{ "version": "2.2", "instance": { "nhwk-20230930x10q.htm": { "nsprefix": "nhwk", "nsuri": "http://www.nighthawkbio.com/20230930", "dts": { "schema": { "local": [ "nhwk-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] }, "calculationLink": { "local": [ "nhwk-20230930_cal.xml" ] }, "definitionLink": { "local": [ "nhwk-20230930_def.xml" ] }, "labelLink": { "local": [ "nhwk-20230930_lab.xml" ] }, "presentationLink": { "local": [ "nhwk-20230930_pre.xml" ] }, "inline": { "local": [ "nhwk-20230930x10q.htm" ] } }, "keyStandard": 330, "keyCustom": 117, "axisStandard": 25, "axisCustom": 0, "memberStandard": 33, "memberCustom": 21, "hidden": { "total": 16, "http://fasb.org/us-gaap/2022": 11, "http://xbrl.sec.gov/dei/2022": 5 }, "contextCount": 195, "entityCount": 1, "segmentCount": 57, "elementCount": 638, "unitCount": 9, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 29, "http://fasb.org/us-gaap/2022": 763 }, "report": { "R1": { "role": "http://www.nighthawkbio.com/role/DocumentDocumentAndEntityInformation", "longName": "00090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets", "longName": "00100 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_9_30_2023_aGabvu7Sa0SZnW1RzU1rrA", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_aGabvu7Sa0SZnW1RzU1rrA", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheetsParenthetical", "longName": "00105 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As_Of_9_30_2023_aGabvu7Sa0SZnW1RzU1rrA", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_1UvhhocaIkW93W1TGHyPZA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_aGabvu7Sa0SZnW1RzU1rrA", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_1UvhhocaIkW93W1TGHyPZA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss", "longName": "00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss", "shortName": "Consolidated Statements of Operations and Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_uXN38TrY-UO2hFLEzDvdBw", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_uXN38TrY-UO2hFLEzDvdBw", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "unique": true } }, "R5": { "role": "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfStockholdersEquity", "longName": "00300 - Statement - Consolidated Statements of Stockholders' Equity", "shortName": "Consolidated Statements of Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hf0iKD2_ckqyCdps2Z4jzA", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_hf0iKD2_ckqyCdps2Z4jzA", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows", "longName": "00400 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_uXN38TrY-UO2hFLEzDvdBw", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "unique": true } }, "R7": { "role": "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies", "longName": "10101 - Disclosure - Basis of Presentation and Significant Accounting Policies", "shortName": "Basis of Presentation and Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperations", "longName": "10201 - Disclosure - Discontinued Operations", "shortName": "Discontinued Operations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.nighthawkbio.com/role/DisclosureAcquisitions", "longName": "10301 - Disclosure - Acquisitions", "shortName": "Acquisitions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstruments", "longName": "10401 - Disclosure - Fair Value of Financial Instruments", "shortName": "Fair Value of Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.nighthawkbio.com/role/DisclosureShortTermInvestments", "longName": "10501 - Disclosure - Short-Term Investments", "shortName": "Short-Term Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.nighthawkbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets", "longName": "10601 - Disclosure - Prepaid Expenses and Other Current Assets", "shortName": "Prepaid Expenses and Other Current Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:OtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:OtherCurrentAssetsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.nighthawkbio.com/role/DisclosurePropertyAndEquipment", "longName": "10701 - Disclosure - Property and Equipment", "shortName": "Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.nighthawkbio.com/role/DisclosureGoodwillAndOtherIntangibleAssets", "longName": "10801 - Disclosure - Goodwill and Other Intangible Assets", "shortName": "Goodwill and Other Intangible Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.nighthawkbio.com/role/DisclosureAccruedExpensesAndOtherLiabilities", "longName": "10901 - Disclosure - Accrued Expenses and Other Liabilities", "shortName": "Accrued Expenses and Other Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.nighthawkbio.com/role/DisclosureStockholdersEquity", "longName": "11001 - Disclosure - Stockholders' Equity", "shortName": "Stockholders' Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.nighthawkbio.com/role/DisclosureRevenue", "longName": "11101 - Disclosure - Revenue", "shortName": "Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.nighthawkbio.com/role/DisclosureNetLossPerShare", "longName": "11201 - Disclosure - Net Loss Per Share", "shortName": "Net Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.nighthawkbio.com/role/DisclosureIncomeTax", "longName": "11301 - Disclosure - Income Tax", "shortName": "Income Tax", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.nighthawkbio.com/role/DisclosureLeases", "longName": "11401 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "nhwk:LeaseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "nhwk:LeaseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.nighthawkbio.com/role/DisclosureCommitmentsAndContingencies", "longName": "11501 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies", "longName": "20102 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)", "shortName": "Basis of Presentation and Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "22", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsTables", "longName": "30203 - Disclosure - Discontinued Operations (Tables)", "shortName": "Discontinued Operations (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.nighthawkbio.com/role/DisclosureAcquisitionsTables", "longName": "30303 - Disclosure - Acquisitions (Tables)", "shortName": "Acquisitions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_us-gaap_BusinessAcquisitionAxis_nhwk_ElusysTherapeuticsMember_M4X4PZ1w202_XHzUE9ibeA", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_us-gaap_BusinessAcquisitionAxis_nhwk_ElusysTherapeuticsMember_M4X4PZ1w202_XHzUE9ibeA", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsTables", "longName": "30403 - Disclosure - Fair Value of Financial Instruments (Tables)", "shortName": "Fair Value of Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.nighthawkbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables", "longName": "30603 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)", "shortName": "Prepaid Expenses and Other Current Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherCurrentAssetsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OtherCurrentAssetsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.nighthawkbio.com/role/DisclosurePropertyAndEquipmentTables", "longName": "30703 - Disclosure - Property and Equipment (Tables)", "shortName": "Property and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.nighthawkbio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsTables", "longName": "30803 - Disclosure - Goodwill and Other Intangible Assets (Tables)", "shortName": "Goodwill and Other Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.nighthawkbio.com/role/DisclosureAccruedExpensesAndOtherLiabilitiesTables", "longName": "30903 - Disclosure - Accrued Expenses and Other Liabilities (Tables)", "shortName": "Accrued Expenses and Other Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityTables", "longName": "31003 - Disclosure - Stockholders' Equity (Tables)", "shortName": "Stockholders' Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.nighthawkbio.com/role/DisclosureRevenueTables", "longName": "31103 - Disclosure - Revenue (Tables)", "shortName": "Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "nhwk:ScheduleOfChangesInContractLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "nhwk:ScheduleOfChangesInContractLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.nighthawkbio.com/role/DisclosureNetLossPerShareTables", "longName": "31203 - Disclosure - Net Loss Per Share (Tables)", "shortName": "Net Loss Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.nighthawkbio.com/role/DisclosureLeasesTables", "longName": "31403 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails", "longName": "40101 - Disclosure - Basis of Presentation and Significant Accounting Policies - Narrative (Details)", "shortName": "Basis of Presentation and Significant Accounting Policies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "As_Of_9_30_2023_aGabvu7Sa0SZnW1RzU1rrA", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "Unit_Standard_segment__lYhqsDrDkOqLmm9YLcL0Q", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "unique": true } }, "R35": { "role": "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfAssetsAndLiabilitiesClassifiedAsHeldForSaleInConsolidatedBalanceSheetsDetails", "longName": "40201 - Disclosure - Discontinued Operations - Schedule of Assets and liabilities classified as held for sale in Consolidated Balance Sheets (Details)", "shortName": "Discontinued Operations - Schedule of Assets and liabilities classified as held for sale in Consolidated Balance Sheets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "As_Of_9_30_2023_aGabvu7Sa0SZnW1RzU1rrA", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsHeldforsaleMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_nhwk_ElusysTherapeuticsIncBusinessMember_xfkAha1U5kmE0tDGA5hVqw", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "unique": true } }, "R36": { "role": "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfDiscontinuedOperationInOperationsStatementDetails", "longName": "40202 - Disclosure - Discontinued Operations - Schedule of discontinued operation in operations statement (Details)", "shortName": "Discontinued Operations - Schedule of discontinued operation in operations statement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "nhwk:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetImpairmentLoss", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_nhwk_ElusysTherapeuticsIncBusinessMember_VyMIA-TBuUKyu0FlSG4-7Q", "name": "nhwk:GoodwillImpairmentLossDiscontinuedOperations", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "unique": true } }, "R37": { "role": "http://www.nighthawkbio.com/role/DisclosureAcquisitionsNarrativeDetails", "longName": "40301 - Disclosure - Acquisitions - Narrative (Details)", "shortName": "Acquisitions - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "As_Of_9_30_2023_aGabvu7Sa0SZnW1RzU1rrA", "name": "nhwk:BusinessCombinationAdditionalEarnOutLiabilitiesOfGrossSalePriceForNumberOfPreFilledVials", "unitRef": "Unit_Standard_item_RwsB_I18gUS7J186m8f3GA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_aGabvu7Sa0SZnW1RzU1rrA", "name": "nhwk:BusinessCombinationAdditionalEarnOutLiabilitiesOfGrossSalePriceForNumberOfPreFilledVials", "unitRef": "Unit_Standard_item_RwsB_I18gUS7J186m8f3GA", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.nighthawkbio.com/role/DisclosureAcquisitionsComponentsOfPurchaseConsiderationDetails", "longName": "40302 - Disclosure - Acquisitions - Components of Purchase Consideration (Details)", "shortName": "Acquisitions - Components of Purchase Consideration (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "Duration_1_1_2022_To_9_30_2022_OAMmtO54yEKTSl_q80Likg", "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_18_2022_To_4_18_2022_us-gaap_BusinessAcquisitionAxis_nhwk_ElusysTherapeuticsMember_Ya0hcrJDyU6KieZU5U50cw", "name": "nhwk:BusinessCombinationEarnOutConsideration", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "unique": true } }, "R39": { "role": "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails", "longName": "40303 - Disclosure - Acquisitions - Purchase Price Allocation (Details)", "shortName": "Acquisitions - Purchase Price Allocation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "As_Of_4_18_2022_us-gaap_BusinessAcquisitionAxis_nhwk_ElusysTherapeuticsMember_epGe-4bke0uGaFLapGNZyA", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_4_18_2022_us-gaap_BusinessAcquisitionAxis_nhwk_ElusysTherapeuticsMember_epGe-4bke0uGaFLapGNZyA", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.nighthawkbio.com/role/DisclosureAcquisitionsSupplementalProFormaFinancialInformationDetails", "longName": "40304 - Disclosure - Acquisitions - Supplemental Pro Forma Financial Information (Details)", "shortName": "Acquisitions - Supplemental Pro Forma Financial Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "Duration_7_1_2022_To_9_30_2022_NFzUdldOL0mpJxyLffwEjQ", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2022_To_9_30_2022_NFzUdldOL0mpJxyLffwEjQ", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWarrantWeightedAverageAssumptionsDetails", "longName": "40401 - Disclosure - Fair Value of Financial Instruments - Schedule of Warrant Weighted Average Assumptions (Details)", "shortName": "Fair Value of Financial Instruments - Schedule of Warrant Weighted Average Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "As_Of_9_30_2023_aGabvu7Sa0SZnW1RzU1rrA", "name": "nhwk:AssetsTransferFromLevel1ToLevel2TransfersAmount1", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "nhwk:AssetsTransferFromLevel1ToLevel2TransfersAmount1", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_aGabvu7Sa0SZnW1RzU1rrA", "name": "nhwk:AssetsTransferFromLevel1ToLevel2TransfersAmount1", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "nhwk:AssetsTransferFromLevel1ToLevel2TransfersAmount1", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueFinancialInstrumentsDetails", "longName": "40402 - Disclosure - Fair Value of Financial Instruments - Schedule of Fair Value Financial Instruments (Details)", "shortName": "Fair Value of Financial Instruments - Schedule of Fair Value Financial Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "As_Of_9_30_2023_aGabvu7Sa0SZnW1RzU1rrA", "name": "us-gaap:DerivativeLiabilitiesNoncurrent", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "us-gaap:DerivativesPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_ovH4JQGbME650TwGHR8o4A", "name": "us-gaap:MarketableSecuritiesCurrent", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "unique": true } }, "R43": { "role": "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsChangeInFairValueDetails", "longName": "40403 - Disclosure - Fair Value of Financial Instruments - Change in Fair Value (Details)", "shortName": "Fair Value of Financial Instruments - Change in Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "As_Of_6_30_2022_us-gaap_BusinessAcquisitionAxis_nhwk_PelicanTherapeuticsIncMember_us-gaap_FairValueByLiabilityClassAxis_nhwk_ContingentConsiderationMember_Rbw8IzYso0qlWM6Ds_wzPQ", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2022_us-gaap_BusinessAcquisitionAxis_nhwk_PelicanTherapeuticsIncMember_us-gaap_FairValueByLiabilityClassAxis_nhwk_ContingentConsiderationMember_Rbw8IzYso0qlWM6Ds_wzPQ", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsNarrativeDetails", "longName": "40404 - Disclosure - Fair Value of Financial Instruments - Narrative (Details)", "shortName": "Fair Value of Financial Instruments - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "Duration_7_1_2022_To_9_30_2022_NFzUdldOL0mpJxyLffwEjQ", "name": "nhwk:ChangeInFairValueOfContingentConsideration", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true }, "uniqueAnchor": null }, "R45": { "role": "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfInputsAndValuationMethodologiesUsedDetails", "longName": "40405 - Disclosure - Fair Value of Financial Instruments - Schedule of Inputs and Valuation Methodologies Used (Details)", "shortName": "Fair Value of Financial Instruments - Schedule of Inputs and Valuation Methodologies Used (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "As_Of_9_30_2023_us-gaap_BusinessAcquisitionAxis_nhwk_ElusysTherapeuticsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_nhwk_RevenueEarnOutMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueDiscountedCashFlowMember_WrGKWgB_UUugeep0cVziOw", "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "unitRef": "Unit_Standard_pure_KQKiR0l_pEOtcai2VbrFmQ", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_us-gaap_BusinessAcquisitionAxis_nhwk_ElusysTherapeuticsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_nhwk_RevenueEarnOutMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueDiscountedCashFlowMember_WrGKWgB_UUugeep0cVziOw", "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "unitRef": "Unit_Standard_pure_KQKiR0l_pEOtcai2VbrFmQ", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.nighthawkbio.com/role/DisclosureShortTermInvestmentsDetails", "longName": "40501 - Disclosure - Short-Term Investments (Details)", "shortName": "Short-Term Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "As_Of_9_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_MutualFundMember_D1r4Myvyn0-3ZSh1C0jCWw", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_us-gaap_FinancialInstrumentAxis_us-gaap_MutualFundMember_D1r4Myvyn0-3ZSh1C0jCWw", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.nighthawkbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails", "longName": "40601 - Disclosure - Prepaid Expenses and Other Current Assets (Details)", "shortName": "Prepaid Expenses and Other Current Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "As_Of_9_30_2023_aGabvu7Sa0SZnW1RzU1rrA", "name": "nhwk:PrepaidManufacturingExpense", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_aGabvu7Sa0SZnW1RzU1rrA", "name": "nhwk:PrepaidManufacturingExpense", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock", "us-gaap:OtherCurrentAssetsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.nighthawkbio.com/role/DisclosurePropertyAndEquipmentDetails", "longName": "40701 - Disclosure - Property and Equipment (Details)", "shortName": "Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "As_Of_9_30_2023_aGabvu7Sa0SZnW1RzU1rrA", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_O6tVsO5KkEWPmcsz3ajnOg", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "unique": true } }, "R49": { "role": "http://www.nighthawkbio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsDetails", "longName": "40801 - Disclosure - Goodwill and Other Intangible Assets (Details)", "shortName": "Goodwill and Other Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "Duration_7_1_2022_To_9_30_2022_NFzUdldOL0mpJxyLffwEjQ", "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2017_To_12_31_2017_us-gaap_BusinessAcquisitionAxis_nhwk_PelicanTherapeuticsIncMember_o4jdGodcX0ee7yW-WPEbYg", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "unique": true } }, "R50": { "role": "http://www.nighthawkbio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsCarryingAmountOfGoodwillAndIntangibleAssetsDetails", "longName": "40802 - Disclosure - Goodwill and Other Intangible Assets - Carrying amount of goodwill and intangible assets (Details)", "shortName": "Goodwill and Other Intangible Assets - Carrying amount of goodwill and intangible assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_ttv6V6TUlEuzcTMsVPez4g", "name": "us-gaap:GoodwillImpairmentLoss", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_us-gaap_BusinessAcquisitionAxis_nhwk_ElusysTherapeuticsMember_M4X4PZ1w202_XHzUE9ibeA", "name": "us-gaap:GoodwillPurchaseAccountingAdjustments", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "unique": true } }, "R51": { "role": "http://www.nighthawkbio.com/role/DisclosureAccruedExpensesAndOtherLiabilitiesDetails", "longName": "40901 - Disclosure - Accrued Expenses and Other Liabilities (Details)", "shortName": "Accrued Expenses and Other Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "As_Of_9_30_2023_aGabvu7Sa0SZnW1RzU1rrA", "name": "us-gaap:AccruedMarketingCostsCurrent", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_aGabvu7Sa0SZnW1RzU1rrA", "name": "us-gaap:AccruedMarketingCostsCurrent", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityChangesInOutstandingWarrantsDetails", "longName": "41001 - Disclosure - Stockholders' Equity - Changes in Outstanding Warrants (Details)", "shortName": "Stockholders' Equity - Changes in Outstanding Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "As_Of_9_30_2023_us-gaap_AwardTypeAxis_nhwk_CommonStockWarrantMember__zRxQZU6h0KtRJfOhwUnFA", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "Unit_Standard_shares_G64qnpu4cU-HAbXL0vqFsw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_us-gaap_AwardTypeAxis_nhwk_CommonStockWarrantMember__zRxQZU6h0KtRJfOhwUnFA", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "Unit_Standard_shares_G64qnpu4cU-HAbXL0vqFsw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityAccountingForStockBasedCompensationDetails", "longName": "41002 - Disclosure - Stockholders' Equity - Accounting for Stock-Based Compensation (Details)", "shortName": "Stockholders' Equity - Accounting for Stock-Based Compensation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_uXN38TrY-UO2hFLEzDvdBw", "name": "us-gaap:ShareBasedCompensation", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_uXN38TrY-UO2hFLEzDvdBw", "name": "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "unique": true } }, "R54": { "role": "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityStockOptionValuationAssumptionsDetails", "longName": "41003 - Disclosure - Stockholders' Equity - Stock Option Valuation Assumptions (Details)", "shortName": "Stockholders' Equity - Stock Option Valuation Assumptions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_uXN38TrY-UO2hFLEzDvdBw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "unitRef": "Unit_Standard_pure_KQKiR0l_pEOtcai2VbrFmQ", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "span", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_uXN38TrY-UO2hFLEzDvdBw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "unitRef": "Unit_Standard_pure_KQKiR0l_pEOtcai2VbrFmQ", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "span", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityStockOptionActivityDetails", "longName": "41004 - Disclosure - Stockholders' Equity - Stock Option Activity (Details)", "shortName": "Stockholders' Equity - Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "As_Of_12_31_2022_O6tVsO5KkEWPmcsz3ajnOg", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_G64qnpu4cU-HAbXL0vqFsw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_O6tVsO5KkEWPmcsz3ajnOg", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_G64qnpu4cU-HAbXL0vqFsw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityRestrictedStockDetails", "longName": "41005 - Disclosure - Stockholders' Equity - Restricted Stock (Details)", "shortName": "Stockholders' Equity - Restricted Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_vOh2kZCUxESYBeHZAv9elQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Unit_Standard_shares_G64qnpu4cU-HAbXL0vqFsw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_vOh2kZCUxESYBeHZAv9elQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Unit_Standard_shares_G64qnpu4cU-HAbXL0vqFsw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.nighthawkbio.com/role/DisclosureRevenueDetails", "longName": "41101 - Disclosure - Revenue (Details)", "shortName": "Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_uXN38TrY-UO2hFLEzDvdBw", "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_uXN38TrY-UO2hFLEzDvdBw", "name": "nhwk:ProcessDevelopmentRevenueRecognized", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "unique": true } }, "R58": { "role": "http://www.nighthawkbio.com/role/DisclosureNetLossPerShareReconciliationOfNetLossDetails", "longName": "41201 - Disclosure - Net Loss Per Share - Reconciliation of Net Loss (Details)", "shortName": "Net Loss Per Share - Reconciliation of Net Loss (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_uXN38TrY-UO2hFLEzDvdBw", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true }, "uniqueAnchor": null }, "R59": { "role": "http://www.nighthawkbio.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails", "longName": "41202 - Disclosure - Net Loss Per Share - Antidilutive Securities (Details)", "shortName": "Net Loss Per Share - Antidilutive Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_pwgqf3lLZ0GC88dHtqVAGA", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_G64qnpu4cU-HAbXL0vqFsw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_pwgqf3lLZ0GC88dHtqVAGA", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_G64qnpu4cU-HAbXL0vqFsw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.nighthawkbio.com/role/DisclosureIncomeTaxDetails", "longName": "41301 - Disclosure - Income Tax (Details)", "shortName": "Income Tax (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_uXN38TrY-UO2hFLEzDvdBw", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_uXN38TrY-UO2hFLEzDvdBw", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.nighthawkbio.com/role/DisclosureLeasesFacilityLeaseDetails", "longName": "41401 - Disclosure - Leases - Facility Lease (Details)", "shortName": "Leases - Facility Lease (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "As_Of_12_31_2022_O6tVsO5KkEWPmcsz3ajnOg", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_15_2022_srt_CounterpartyNameAxis_nhwk_MerchantsIceIiLlcMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_8IHKfkCyfkC9xjEYvfjg4w", "name": "nhwk:OperatingLeaseReimbursementOfExpensesCapitalized", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "nhwk:LeaseDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "unique": true } }, "R62": { "role": "http://www.nighthawkbio.com/role/DisclosureLeasesLeaseCostDetails", "longName": "41402 - Disclosure - Leases - Lease Cost (Details)", "shortName": "Leases - Lease Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_uXN38TrY-UO2hFLEzDvdBw", "name": "us-gaap:OperatingLeasePayments", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_uXN38TrY-UO2hFLEzDvdBw", "name": "us-gaap:OperatingLeasePayments", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails", "longName": "41403 - Disclosure - Leases - Maturities of Operating and Finance Lease Liabilities (Details)", "shortName": "Leases - Maturities of Operating and Finance Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "As_Of_9_30_2023_aGabvu7Sa0SZnW1RzU1rrA", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "nhwk:ScheduleOfFutureLeaseLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_aGabvu7Sa0SZnW1RzU1rrA", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "nhwk:ScheduleOfFutureLeaseLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.nighthawkbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "longName": "41501 - Disclosure - Commitments and Contingencies - Narrative (Details)", "shortName": "Commitments and Contingencies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_nhwk_AnthimDrugSubstanceMember_fQtdrg5EdEettSwD9ZlAqQ", "name": "us-gaap:LongTermPurchaseCommitmentAmount", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_nhwk_AnthimDrugSubstanceMember_fQtdrg5EdEettSwD9ZlAqQ", "name": "us-gaap:LongTermPurchaseCommitmentAmount", "unitRef": "Unit_Standard_USD_W0n2y9j7JEOSMZluRw-L2g", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "nhwk-20230930x10q.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsChangeInFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Change in fair value", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsChangeInFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "terseLabel": "Change in fair value", "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r449" ] }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "terseLabel": "Schedule of restricted stock activity", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares." } } }, "auth_ref": [ "r109" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsChangeInFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityStockOptionValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value (in dollars per share)", "documentation": "Weighted average grant-date fair value of options vested." } } }, "auth_ref": [] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "RestrictedStockMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityRestrictedStockDetails" ], "lang": { "en-us": { "role": { "label": "Restricted stock", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r76" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule of change in fair value, as determined by Level 3 inputs, for all assets and liabilities using unobservable Level 3 inputs", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": [ "r153", "r155" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityStockOptionValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Expected term (years)", "terseLabel": "Expected lives (years)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r391" ] }, "us-gaap_FurnitureAndFixturesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FurnitureAndFixturesMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosurePropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Furniture and fixtures", "terseLabel": "Furniture and fixtures", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r76" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year", "verboseLabel": "2023 (excluding the nine months ended September 30, 2023)", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r641" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Stock options exercisable at end of period", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r118" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWarrantWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net", "terseLabel": "Level 3 Asset transferred, net", "documentation": "Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r76" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Net Loss Per Share", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r66" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Potentially dilutive securities", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r244" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWarrantWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net", "terseLabel": "Level 3 liabilities transferred, net", "documentation": "Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted average remaining contractual life.", "terseLabel": "Stock options exercisable at end of period", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r118" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Flows from Financing Activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net Cash (Used In) Provided by Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r64", "r65", "r68" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Stock options outstanding at end of period", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r116" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net Cash Provided By Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r213" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "RangeAxis", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.nighthawkbio.com/role/DisclosureRevenueDetails", "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityAccountingForStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Range [Axis]" } } }, "auth_ref": [ "r309", "r310", "r311", "r312", "r359", "r366", "r392", "r393", "r394", "r481", "r505", "r525", "r546", "r547", "r566", "r574", "r583", "r621", "r627", "r646", "r647", "r648", "r649", "r650" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "RangeMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.nighthawkbio.com/role/DisclosureRevenueDetails", "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityAccountingForStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r309", "r310", "r311", "r312", "r359", "r366", "r392", "r393", "r394", "r481", "r505", "r525", "r546", "r547", "r566", "r574", "r583", "r621", "r627", "r646", "r647", "r648", "r649", "r650" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net Cash Used In Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r213" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r473" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five", "terseLabel": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r473" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Flows from Investing Activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Flows from Operating Activities" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureNetLossPerShareReconciliationOfNetLossDetails", "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net loss attributable to NightHawk Biosciences, Inc.", "verboseLabel": "Net loss attributable to NightHawk", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r51", "r68", "r167", "r177", "r187", "r198", "r201", "r206", "r216", "r226", "r228", "r229", "r230", "r231", "r234", "r235", "r240", "r258", "r266", "r270", "r272", "r286", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r443", "r452", "r559", "r625" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.nighthawkbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 22.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable", "verboseLabel": "Accounts payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r66" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 }, "http://www.nighthawkbio.com/role/DisclosureAccruedExpensesAndOtherLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAccruedExpensesAndOtherLiabilitiesDetails", "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses and other liabilities", "totalLabel": "Accrued expenses and other current liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r35" ] }, "us-gaap_GrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "GrantMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Grant and contract revenue", "documentation": "Award of money not required to be repaid." } } }, "auth_ref": [ "r629" ] }, "us-gaap_TransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "TransactionDomain", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Transaction [Domain]", "documentation": "Agreement between buyer and seller for the exchange of financial instruments." } } }, "auth_ref": [ "r553" ] }, "us-gaap_TransactionTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "TransactionTypeAxis", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Transaction Type [Axis]", "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments." } } }, "auth_ref": [ "r553" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesFacilityLeaseDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r220", "r221", "r322", "r326", "r552", "r553" ] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesFacilityLeaseDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Lease renewal term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r639" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 24.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "verboseLabel": "Accrued expenses and other liabilities", "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other." } } }, "auth_ref": [ "r601" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfAssetsAndLiabilitiesClassifiedAsHeldForSaleInConsolidatedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent", "terseLabel": "Other assets", "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r0", "r1", "r18", "r91", "r97" ] }, "nhwk_ContractAmountRetained": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "ContractAmountRetained", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "The contract amount retained.", "label": "Contract Amount Retained", "terseLabel": "Contract amount retained" } } }, "auth_ref": [] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AssetsAbstract", "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "verboseLabel": "Assets" } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LongTermPurchaseCommitmentAmount", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Purchase Commitment, Amount", "terseLabel": "Future commitments", "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityRegistrantName", "presentation": [ "http://www.nighthawkbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r585" ] }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DerivativesPolicyTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Derivatives, Policy [Policy Text Block]", "verboseLabel": "Derivative Financial Instruments", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": [ "r145", "r146", "r147", "r148", "r151", "r222" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfAssetsAndLiabilitiesClassifiedAsHeldForSaleInConsolidatedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net", "terseLabel": "Accounts receivable", "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r0", "r1", "r18", "r97" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "LegalEntityAxis", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityTotalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StockholdersEquityTotalMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Stockholders", "documentation": "Carrying amount as of the balance sheet date of total stockholders' equity, when it serves as a benchmark in a concentration of risk calculation. Also called Net Assets." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfDiscontinuedOperationInOperationsStatementDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold", "terseLabel": "Cost of revenues", "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r17", "r187" ] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StockholdersEquityNoteAbstract", "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity", "verboseLabel": "Stockholders' Equity" } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityDomain", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfAssetsAndLiabilitiesClassifiedAsHeldForSaleInConsolidatedBalanceSheetsDetails", "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfDiscontinuedOperationInOperationsStatementDetails", "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": [ "r572", "r573" ] }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ImpairmentOfIntangibleAssetsFinitelived", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 }, "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsDetails", "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Impairment of Intangible Assets, Finite-lived", "terseLabel": "In-process research and development impairment", "verboseLabel": "Intangible asset impairment loss", "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value." } } }, "auth_ref": [ "r602", "r620" ] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperations" ], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "terseLabel": "Discontinued Operations", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r25", "r100" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.nighthawkbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r585" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfDiscontinuedOperationInOperationsStatementDetails", "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Revenue", "terseLabel": "Revenue", "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r17", "r187" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityFileNumber", "presentation": [ "http://www.nighthawkbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "nhwk_DeferredTaxLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "DeferredTaxLiability", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash out flow to deferred tax liabilities.", "label": "Deferred tax liability", "negatedLabel": "Deferred tax liability" } } }, "auth_ref": [] }, "nhwk_DisposalGroupIncludingDiscontinuedOperationAmountPaidToSeller": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "DisposalGroupIncludingDiscontinuedOperationAmountPaidToSeller", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of cash paid to seller of discontinued operation", "label": "Disposal Group Including Discontinued Operation Amount Paid To Seller", "terseLabel": "Disposal group including discontinued operation Amount paid to seller" } } }, "auth_ref": [] }, "nhwk_GoodwillImpairmentLossDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "GoodwillImpairmentLossDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfDiscontinuedOperationInOperationsStatementDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized related to discontinued operations.", "label": "Goodwill Impairment Loss Discontinued Operations", "terseLabel": "Goodwill impairment loss" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Note 9 and 13)", "terseLabel": "Commitments and Contingencies (Note 13 and Note 14)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r37", "r163", "r174" ] }, "nhwk_IncreaseDecreaseInLiabilityForUncertainTaxPositions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "IncreaseDecreaseInLiabilityForUncertainTaxPositions", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in liability for uncertain tax positions.", "label": "Increase (Decrease) in Liability for Uncertain Tax Positions", "terseLabel": "Increase in liability for uncertain tax positions" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r158", "r169", "r194", "r216", "r258", "r267", "r271", "r286", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r433", "r437", "r452", "r580", "r625", "r626", "r643" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.nighthawkbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r585" ] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "StatementScenarioAxis", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "auth_ref": [ "r236", "r367", "r590", "r591", "r607" ] }, "nhwk_ChangeInFairValueOfContingentConsiderationDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "ChangeInFairValueOfContingentConsiderationDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsNarrativeDetails", "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Change in fair value of contingent consideration related to contingent considerations.", "label": "Change In Fair Value Of Contingent Consideration Discontinued Operations", "terseLabel": "Change in fair value of contingent consideration" } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Purchase Commitment, Category of Item Purchased [Domain]", "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment." } } }, "auth_ref": [] }, "nhwk_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetImpairmentLoss", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfDiscontinuedOperationInOperationsStatementDetails", "http://www.nighthawkbio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsCarryingAmountOfGoodwillAndIntangibleAssetsDetails", "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of intangible asset impairment loss attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Intangible Asset Impairment Loss", "negatedLabel": "Impairment", "terseLabel": "Intangible asset impairment loss" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncreaseDecreaseInDeferredRevenue", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 23.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Deferred Revenue", "verboseLabel": "Deferred revenue", "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r554" ] }, "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncreaseDecreaseInIncomeTaxesReceivable", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Income Taxes Receivable", "negatedLabel": "Income tax receivable", "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid." } } }, "auth_ref": [ "r66" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.nighthawkbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.nighthawkbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesFacilityLeaseDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": [ "r274", "r275", "r532", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r568", "r582", "r628" ] }, "us-gaap_IncreaseDecreaseInDeferredLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncreaseDecreaseInDeferredLiabilities", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Deferred Liabilities", "terseLabel": "Increase in deferred tax liability", "documentation": "Change during the period in carrying value for all deferred liabilities due within one year or operating cycle." } } }, "auth_ref": [ "r66" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies" } } }, "auth_ref": [] }, "us-gaap_InProcessResearchAndDevelopmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "InProcessResearchAndDevelopmentMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "In-process R&D.", "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "verboseLabel": "Income Tax", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r203", "r402", "r403", "r410", "r411", "r412", "r414" ] }, "nhwk_LeaseLiabilityToBePaidYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "LeaseLiabilityToBePaidYearFive", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": { "parentTag": "nhwk_LeaseLiabilityPaymentDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lease, Liability, to be Paid, Year Five", "terseLabel": "2028" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "LocalPhoneNumber", "presentation": [ "http://www.nighthawkbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfAssetsAndLiabilitiesClassifiedAsHeldForSaleInConsolidatedBalanceSheetsDetails", "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Assets, Noncurrent", "terseLabel": "Non-current assets held for sale", "totalLabel": "Total long term assets", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r0", "r1", "r18", "r91", "r97", "r186", "r187" ] }, "nhwk_LeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "LeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureLeasesScheduleOfOperatingLeaseLiabilitiesMaturitiesDetailsCalc2": { "parentTag": "nhwk_LeaseLiabilityPaymentDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for lease.", "label": "Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: imputed interest" } } }, "auth_ref": [] }, "nhwk_ElusysTherapeuticsIncBusinessMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "ElusysTherapeuticsIncBusinessMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfAssetsAndLiabilitiesClassifiedAsHeldForSaleInConsolidatedBalanceSheetsDetails", "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfDiscontinuedOperationInOperationsStatementDetails", "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information relating to Elusys Therapeutics, Inc. business divestiture.", "label": "Elusys Therapeutics, Inc Business [Member]", "terseLabel": "Elusys Therapeutics business" } } }, "auth_ref": [] }, "nhwk_LeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "LeaseLiability", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureLeasesScheduleOfOperatingLeaseLiabilitiesMaturitiesDetailsCalc2": { "parentTag": "nhwk_LeaseLiabilityPaymentDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments for lease.", "label": "Lease, Liability", "terseLabel": "Present value of lease liabilities" } } }, "auth_ref": [] }, "nhwk_DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedExpensesAndOtherLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfAssetsAndLiabilitiesClassifiedAsHeldForSaleInConsolidatedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount classified as accrued land other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Accrued Expenses and Other Liabilities, Current", "terseLabel": "Accrued expenses and other liabilities" } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.nighthawkbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r587" ] }, "nhwk_IncreaseDecreaseInOperatingLeaseRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssets", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 21.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the value of operating lease right of use assets.", "label": "Increase Decrease In Operating Lease Right Of Use Assets", "negatedLabel": "Right-of-use assets" } } }, "auth_ref": [] }, "nhwk_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "DisposalGroupIncludingDiscontinuedOperationContingentConsiderationNoncurrent", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfAssetsAndLiabilitiesClassifiedAsHeldForSaleInConsolidatedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount classified as contingent consideration attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Contingent Consideration, Noncurrent", "terseLabel": "Contingent consideration, net of current portion" } } }, "auth_ref": [] }, "nhwk_DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "DisposalGroupIncludingDiscontinuedOperationResearchAndDevelopmentExpenses", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfDiscontinuedOperationInOperationsStatementDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of research and development expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Research and Development Expenses", "terseLabel": "Research and development" } } }, "auth_ref": [] }, "nhwk_LeaseLiabilityToBePaidRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "LeaseLiabilityToBePaidRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": { "parentTag": "nhwk_LeaseLiabilityPaymentDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lease Liability To Be Paid Remainder Of The Fiscal Year", "terseLabel": "2023 (excluding the nine months ended September 30, 2023)" } } }, "auth_ref": [] }, "nhwk_DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "DisposalGroupIncludingDiscontinuedOperationChangeInFairValueOfContingentConsideration", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfDiscontinuedOperationInOperationsStatementDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of change in fair value of contingent consideration attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Change in Fair Value of Contingent Consideration", "terseLabel": "Change in fair value of contingent consideration" } } }, "auth_ref": [] }, "nhwk_RiskAndUncertaintiesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "RiskAndUncertaintiesPolicyTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to risks and Uncertainties.", "label": "Risk and Uncertainties [Policy Text Block]", "terseLabel": "Risk and Uncertainties" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "negatedLabel": "Net loss from continuing operations", "totalLabel": "Net loss from continuing operations before income taxes", "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r137", "r216", "r226", "r258", "r266", "r270", "r272", "r286", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r443", "r452", "r559", "r625" ] }, "nhwk_DisposalGroupIncludingDiscontinuedOperationContingentConsiderationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "DisposalGroupIncludingDiscontinuedOperationContingentConsiderationCurrent", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfAssetsAndLiabilitiesClassifiedAsHeldForSaleInConsolidatedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount classified as contingent consideration attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Contingent Consideration, Current", "terseLabel": "Contingent consideration, current portion" } } }, "auth_ref": [] }, "nhwk_RoyaltyPercentageAfterThresholdIsMet": { "xbrltype": "percentItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "RoyaltyPercentageAfterThresholdIsMet", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Royalty percentage after threshold is met.", "label": "Royalty Percentage After Threshold Is Met", "terseLabel": "Royalty percentage after threshold is met" } } }, "auth_ref": [] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureRevenueDetails", "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r277", "r278" ] }, "nhwk_RevenueFromContractWithCustomerLiabilityPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "RevenueFromContractWithCustomerLiabilityPolicyTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer liability.", "label": "Revenue from Contract with Customer Liability [Policy Text Block]", "terseLabel": "Deferred Revenue" } } }, "auth_ref": [] }, "nhwk_DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpensesAbstract", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfDiscontinuedOperationInOperationsStatementDetails" ], "lang": { "en-us": { "role": { "documentation": "N/A", "label": "Discontinued operation operating expense", "terseLabel": "Discontinued operation operating expense" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureNetLossPerShareReconciliationOfNetLossDetails", "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "terseLabel": "Net loss - non-controlling interest", "verboseLabel": "Net loss - Non-controlling interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r140", "r143", "r198", "r201", "r234", "r235", "r600" ] }, "nhwk_AmortizationOfIntangibleAssetsExcludingGoodwillDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "AmortizationOfIntangibleAssetsExcludingGoodwillDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfDiscontinuedOperationInOperationsStatementDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to intangible assets other than goodwill of discontinued operations.", "label": "Amortization of Intangible Assets Excluding Goodwill Discontinued Operations", "terseLabel": "Amortization of intangible asset" } } }, "auth_ref": [] }, "nhwk_DisposalGroupIncludingDiscontinuedOperationNonOperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "DisposalGroupIncludingDiscontinuedOperationNonOperatingIncomeLoss", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfDiscontinuedOperationInOperationsStatementDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of non operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Non Operating Income (Loss)", "totalLabel": "Total non-operating income (loss)" } } }, "auth_ref": [] }, "nhwk_BusinessCombinationAdditionalEarnOutLiabilitiesOfGrossSalePriceForNumberOfPreFilledVials": { "xbrltype": "integerItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "BusinessCombinationAdditionalEarnOutLiabilitiesOfGrossSalePriceForNumberOfPreFilledVials", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents number of pre-filled vials for which the additional earn out liability of the estimated gross sales price is considered for calculation.", "label": "Business Combination Additional Earn Out Liabilities Of Gross Sale Price For Number of Pre-filled Vials", "terseLabel": "Business combination additional earn out liabilities of gross sale price for number of pre-filled Vials" } } }, "auth_ref": [] }, "nhwk_DisposalGroupIncludingDiscontinuedOperationOtherExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherExpenseNet", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfDiscontinuedOperationInOperationsStatementDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of other income net of expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Other Expense, Net", "terseLabel": "Other expense, net" } } }, "auth_ref": [] }, "nhwk_NumberOfVialsManufacturingConversionCompleted": { "xbrltype": "integerItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "NumberOfVialsManufacturingConversionCompleted", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of vials for which manufacturing conversion is completed.", "label": "Number Of Vials, Manufacturing Conversion Completed", "terseLabel": "Number of vials, manufacturing conversion" } } }, "auth_ref": [] }, "nhwk_LeaseLiabilityPaymentDue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "LeaseLiabilityPaymentDue", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureLeasesScheduleOfOperatingLeaseLiabilitiesMaturitiesDetailsCalc2": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for lease.", "label": "Lease, Liability, Payment, Due", "totalLabel": "Total minimum lease payments" } } }, "auth_ref": [] }, "nhwk_FiniteLivedIntangibleAssetsReclassifiedToDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "FiniteLivedIntangibleAssetsReclassifiedToDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsCarryingAmountOfGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of finite lived intangible assets reclassified into discontinued operations.", "label": "Finite-Lived Intangible Assets, Reclassified to Discontinued Operations", "terseLabel": "Reclassified to discontinued operations" } } }, "auth_ref": [] }, "nhwk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToHeldForSale": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationToHeldForSale", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsChangeInFairValueDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of payment related to reclassification to held for sale.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Reclassification To Held For Sale", "terseLabel": "Reclassification to held for sale" } } }, "auth_ref": [] }, "us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PaymentForContingentConsiderationLiabilityInvestingActivities", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payment for Contingent Consideration Liability, Investing Activities", "negatedLabel": "Payment of contingent consideration", "documentation": "Amount of cash outflow, made soon after acquisition date of business combination, to settle contingent consideration liability." } } }, "auth_ref": [ "r61" ] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DisposalGroupClassificationDomain", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfAssetsAndLiabilitiesClassifiedAsHeldForSaleInConsolidatedBalanceSheetsDetails", "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfDiscontinuedOperationInOperationsStatementDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "Security12bTitle", "presentation": [ "http://www.nighthawkbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r584" ] }, "nhwk_PrepaidExpensesAndOtherCurrentAssetsDetailsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "PrepaidExpensesAndOtherCurrentAssetsDetailsAbstract", "lang": { "en-us": { "role": { "label": "Prepaid Expenses And Other Current Assets" } } }, "auth_ref": [] }, "nhwk_BusinessCombinationReceivableConsiderationBalance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "BusinessCombinationReceivableConsiderationBalance", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Business Combination Receivable Consideration Balance", "label": "Business Combination Receivable Consideration Balance", "terseLabel": "Holding back related to future fulfillment cost" } } }, "auth_ref": [] }, "nhwk_StockholdersEquityScheduleOfWarrantActivityDetailsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "StockholdersEquityScheduleOfWarrantActivityDetailsAbstract", "lang": { "en-us": { "role": { "label": "Stockholders' Equity Schedule Of Warrant Activity Details" } } }, "auth_ref": [] }, "nhwk_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "The accounting policy for prepaid expenses and other current assets.", "label": "Prepaid Expenses And Other Current Assets [Policy Text Block]", "terseLabel": "Prepaid Expenses and Other Current Assets" } } }, "auth_ref": [] }, "nhwk_ReimbursementIncludedInFinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "ReimbursementIncludedInFinanceLeaseRightOfUseAsset", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesFacilityLeaseDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of reimbursement included in the finance lease right of use asset.", "label": "Reimbursement Included in Finance Lease Right of Use Asset", "terseLabel": "Reimbursement included in finance lease right of use asset" } } }, "auth_ref": [] }, "nhwk_DiscontinuedOperationOperatingLeaseRightOfUseAssetNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "DiscontinuedOperationOperatingLeaseRightOfUseAssetNoncurrent", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfAssetsAndLiabilitiesClassifiedAsHeldForSaleInConsolidatedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount classified as operating lease right of use asset, attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.", "label": "Discontinued Operation, Operating Lease Right Of Use Asset, Noncurrent", "terseLabel": "Operating lease right-of-use asset" } } }, "auth_ref": [] }, "nhwk_SignificantAccountingPoliciesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "SignificantAccountingPoliciesPolicyTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for significant accounting policies.", "label": "Significant Accounting Policies [Policy Text Block]", "terseLabel": "Significant Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfAssetsAndLiabilitiesClassifiedAsHeldForSaleInConsolidatedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent", "terseLabel": "Other liabilities", "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r0", "r1", "r18", "r91", "r97" ] }, "nhwk_FiniteLivedIntangibleAssetsWrittenDown": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "FiniteLivedIntangibleAssetsWrittenDown", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of finite lived intangible assets written down", "label": "Finite Lived Intangible Assets Written Down", "terseLabel": "Carrying value written down" } } }, "auth_ref": [] }, "nhwk_TrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "TrancheOneMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Tranche I [Member]", "label": "Tranche 1" } } }, "auth_ref": [] }, "nhwk_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiabilityModifications": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiabilityModifications", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability modifications.", "label": "Right Of Use Asset Obtained In Exchange For Finance Lease Liability Modifications", "verboseLabel": "Right-of-use assets surrendered upon financing lease modifications" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfDiscontinuedOperationInOperationsStatementDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)", "totalLabel": "Loss from operations", "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r17" ] }, "us-gaap_PrepaidInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PrepaidInsurance", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Prepaid insurance", "terseLabel": "Prepaid insurance", "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r549", "r561", "r615" ] }, "nhwk_AnthimDrugSubstanceMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "AnthimDrugSubstanceMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to ANTHIM drug substance.", "label": "ANTHIM Drug Substance [Member]", "terseLabel": "ANTHIM" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "TradingSymbol", "presentation": [ "http://www.nighthawkbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "nhwk_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfAssetsAndLiabilitiesClassifiedAsHeldForSaleInConsolidatedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount classified as operating lease liability attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Operating Lease Liability, Current", "terseLabel": "Operating lease liability, current portion" } } }, "auth_ref": [] }, "nhwk_TrancheTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "TrancheTwoMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Tranche II [Member]", "label": "Tranche 2" } } }, "auth_ref": [] }, "nhwk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityRestrictedStockDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, released during the reporting period.", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Released In Period", "terseLabel": "Released" } } }, "auth_ref": [] }, "nhwk_LicenseRevenueMilestonePaymentsReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "LicenseRevenueMilestonePaymentsReceived", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of revenue received as milestone payments.", "label": "License Revenue, Milestone Payments Received", "terseLabel": "Proceeds from milestone payment" } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SecurityExchangeName", "presentation": [ "http://www.nighthawkbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r586" ] }, "nhwk_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityRestrictedStockDetails" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award released during the period.", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Released In Period, Weighted Average Grant Date Fair Value", "terseLabel": "Released" } } }, "auth_ref": [] }, "nhwk_NoncashLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "NoncashLeaseExpense", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Noncash lease expenses made by the entity during the period.", "label": "Noncash Lease Expense", "terseLabel": "Noncash lease expense" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfAssetsAndLiabilitiesClassifiedAsHeldForSaleInConsolidatedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Accounts Payable, Current", "terseLabel": "Accounts payable", "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r0", "r1", "r18", "r92", "r97" ] }, "nhwk_LeaseDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "LeaseDisclosureTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeases" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of information about leases.", "label": "Lease Disclosure [Text Block]", "terseLabel": "Leases" } } }, "auth_ref": [] }, "us-gaap_PrepaidRent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PrepaidRent", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesFacilityLeaseDetails" ], "lang": { "en-us": { "role": { "label": "Prepaid rent to lessor", "documentation": "Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r550", "r562", "r615" ] }, "nhwk_DisposalGroupIncludingDiscontinuedOperationDepositsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "DisposalGroupIncludingDiscontinuedOperationDepositsNoncurrent", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfAssetsAndLiabilitiesClassifiedAsHeldForSaleInConsolidatedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount classified as deposits attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Deposits, Noncurrent", "terseLabel": "Deposits" } } }, "auth_ref": [] }, "nhwk_DisposalGroupIncludingDiscontinuedOperationIncomeTaxReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "DisposalGroupIncludingDiscontinuedOperationIncomeTaxReceivableCurrent", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfAssetsAndLiabilitiesClassifiedAsHeldForSaleInConsolidatedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount classified as income tax receivable attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Income Tax Receivable, Current", "terseLabel": "Income tax refund receivable" } } }, "auth_ref": [] }, "nhwk_TrancheThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "TrancheThreeMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information regarding Tranche Three.", "label": "Tranche 3" } } }, "auth_ref": [] }, "nhwk_LeaseLiabilityToBePaidYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "LeaseLiabilityToBePaidYearFour", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": { "parentTag": "nhwk_LeaseLiabilityPaymentDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lease, Liability, to be Paid, Year Four", "terseLabel": "2027" } } }, "auth_ref": [] }, "nhwk_ProcessDevelopmentRevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "ProcessDevelopmentRevenueAbstract", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "N/A", "label": "Process Development Revenue [Abstract]", "terseLabel": "Process Development Revenue" } } }, "auth_ref": [] }, "nhwk_ProcessDevelopmentContractLiabilityNetChangeToContractBalance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "ProcessDevelopmentContractLiabilityNetChangeToContractBalance", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of process development contract liability net changes to contract balance recognized since beginning of period due to amounts collected.", "label": "Process Development Contract Liability, Net Change To Contract Balance", "negatedLabel": "Net change to contract balance recognized since beginning of period due to amounts collected" } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentTransitionReport", "presentation": [ "http://www.nighthawkbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "terseLabel": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r588" ] }, "nhwk_ScheduleOfFutureLeaseLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "ScheduleOfFutureLeaseLiabilitiesTableTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturities of operating and finance lease liabilities.", "label": "Schedule of Future Lease Liabilities [Table Text Block]", "terseLabel": "Schedule of maturities of operating and finance lease liabilities" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfAssetsAndLiabilitiesClassifiedAsHeldForSaleInConsolidatedBalanceSheetsDetails", "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents", "terseLabel": "Cash and cash equivalents included in current assets held for sale", "verboseLabel": "Cash and cash equivalents", "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r0", "r1", "r18", "r97" ] }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "MinorityInterestOwnershipPercentageByParent", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest, Ownership Percentage by Parent", "terseLabel": "Ownership interest in subsidiary", "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage." } } }, "auth_ref": [] }, "nhwk_ScheduleOfChangesInContractLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "ScheduleOfChangesInContractLiabilitiesTableTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureRevenueTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in process development contract liabilities.", "label": "Schedule of Changes in Contract Liabilities [Table Text Block]", "terseLabel": "Schedule of changes in contract liabilities" } } }, "auth_ref": [] }, "nhwk_CpritFundingPlanEmployerMatchingContributionsTotalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "CpritFundingPlanEmployerMatchingContributionsTotalAmount", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of Contribution to be made in matching funds over the life of a project.", "label": "CPRIT Funding Plan, Employer Matching Contributions Total, Amount", "terseLabel": "Contribution to be made by Pelican" } } }, "auth_ref": [] }, "nhwk_Fin48TaxLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "Fin48TaxLiabilityNoncurrent", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of FIN48 tax liability, classified as noncurrent.", "label": "FIN48 Tax Liability, Noncurrent", "verboseLabel": "Other liabilities" } } }, "auth_ref": [] }, "us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PaymentForContingentConsiderationLiabilityOperatingActivities", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 26.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payment for Contingent Consideration Liability, Operating Activities", "negatedLabel": "Payment of contingent consideration", "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date." } } }, "auth_ref": [ "r63" ] }, "nhwk_IncomeTaxBenefitRecognizedAsDiscreteItem": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "IncomeTaxBenefitRecognizedAsDiscreteItem", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "documentation": "This element represents the amount of income tax benefit recognized as discrete item during the period", "label": "Income Tax Benefit Recognized As Discrete Item", "terseLabel": "Income tax benefit recognized as discrete item" } } }, "auth_ref": [] }, "nhwk_LeaseLiabilityPaymentDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "LeaseLiabilityPaymentDueAbstract", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "No Definition available.", "label": "Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Maturities of lease liabilities" } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.nighthawkbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "nhwk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFin48TaxLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFin48TaxLiability", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPreliminaryPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of FIN48 tax liability assumed at the acquisition date, in a business combination.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, FIN48 Tax Liability", "negatedLabel": "Other liabilities" } } }, "auth_ref": [] }, "nhwk_LeaseLiabilityToBePaidYearOne": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "LeaseLiabilityToBePaidYearOne", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": { "parentTag": "nhwk_LeaseLiabilityPaymentDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lease, Liability, to be Paid, Year One", "terseLabel": "2024" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfDiscontinuedOperationInOperationsStatementDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense", "terseLabel": "Selling, general and administrative", "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r17" ] }, "nhwk_OtherLiabilitiesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "OtherLiabilitiesPolicyTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for other liabilities.", "label": "Other Liabilities [Policy Text Block]", "terseLabel": "Other Liabilities" } } }, "auth_ref": [] }, "nhwk_LeaseLiabilityToBePaidYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "LeaseLiabilityToBePaidYearTwo", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": { "parentTag": "nhwk_LeaseLiabilityPaymentDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lease, Liability, to be Paid, Year Two", "terseLabel": "2025" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfDiscontinuedOperationInOperationsStatementDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Operating Expense", "totalLabel": "Total operating expenses", "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation." } } }, "auth_ref": [ "r17" ] }, "nhwk_ScorpiusTherapeuticsInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "ScorpiusTherapeuticsInc.Member", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information related to Scorpius Therapeutics, Inc.", "label": "Scorpius Therapeutics, Inc.[Member]", "terseLabel": "Scorpius Therapeutics, Inc." } } }, "auth_ref": [] }, "nhwk_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPaymentOfContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPaymentOfContingentConsideration", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsChangeInFairValueDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of payment related to contingent consideration.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Payment Of Contingent Consideration", "terseLabel": "Payment of contingent consideration" } } }, "auth_ref": [] }, "nhwk_LeaseLiabilityToBePaidYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "LeaseLiabilityToBePaidYearThree", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": { "parentTag": "nhwk_LeaseLiabilityPaymentDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lease, Liability, to be Paid, Year Three", "terseLabel": "2026" } } }, "auth_ref": [] }, "nhwk_MerchantsIceIiLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "MerchantsIceIiLlcMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesFacilityLeaseDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information related to Merchants Ice II, LLC.", "label": "Merchants Ice II, LLC" } } }, "auth_ref": [] }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DerivativeLiabilitiesNoncurrent", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Derivative Liability, Noncurrent", "terseLabel": "Derivative warrant liability", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r197" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureRevenue" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r345", "r346", "r347", "r348", "r349", "r350", "r352", "r353", "r357", "r358" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Issuance of common stock from vesting of restricted stock awards", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": [ "r103", "r104" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 16.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r66" ] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock - ESPP", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": [ "r26", "r27", "r103", "r104" ] }, "us-gaap_OtherPrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "OtherPrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Other prepaid expenses and current assets", "terseLabel": "Other prepaid expenses and current assets", "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r595", "r615" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense", "terseLabel": "Research and development", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r120", "r180", "r651" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total Stockholders' Equity - NightHawk Biosciences, Inc.", "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity." } } }, "auth_ref": [ "r27", "r30", "r31", "r80", "r580", "r603", "r614", "r637" ] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Policy Text Block]", "terseLabel": "Accounts Receivable", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r181", "r182", "r183", "r279", "r280", "r281" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "Stockholders' Equity", "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income." } } }, "auth_ref": [ "r106", "r215", "r325", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r338", "r340", "r440" ] }, "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncreaseDecreaseInOperatingAssetsAbstract", "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) in cash arising from changes in assets and liabilities, net of acquisitions:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherDeferredLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncreaseDecreaseInOtherDeferredLiability", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Deferred Liability", "terseLabel": "Deferred tax liability", "documentation": "Amount of increase (decrease) in deferred obligations classified as other." } } }, "auth_ref": [ "r66" ] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r555", "r556" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 19.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r66" ] }, "us-gaap_MeasurementInputRevenueMultipleMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "MeasurementInputRevenueMultipleMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfInputsAndValuationMethodologiesUsedDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Revenue Multiple [Member]", "terseLabel": "Future revenue projections", "documentation": "Measurement input using market valuation of entity divided by revenue." } } }, "auth_ref": [ "r636" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets", "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "Total Stockholders' Equity", "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity." } } }, "auth_ref": [ "r135", "r136", "r142", "r184", "r185", "r205", "r223", "r224", "r225", "r227", "r233", "r287", "r340", "r398", "r399", "r400", "r415", "r416", "r441", "r453", "r454", "r459", "r474", "r527", "r528", "r603", "r614", "r637" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfInputsAndValuationMethodologiesUsedDetails", "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWarrantWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWarrantWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Risk free interest rate", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": [ "r636" ] }, "us-gaap_MeasurementInputSharePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "MeasurementInputSharePriceMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWarrantWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Current stock price", "documentation": "Measurement input using share price of saleable stock." } } }, "auth_ref": [ "r636" ] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosurePropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Leasehold Improvements", "terseLabel": "Leasehold improvements", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r94" ] }, "us-gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FinanceLeaseLiability", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureLeasesScheduleOfOperatingLeaseLiabilitiesMaturitiesDetailsCalc2": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesFacilityLeaseDetails", "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability", "terseLabel": "Present value of lease liabilities", "verboseLabel": "Finance lease liability", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } }, "auth_ref": [ "r461", "r473" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, Payments, Due Year Four", "terseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r473" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, Payments, Due Year Five", "terseLabel": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r473" ] }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term (years), Finance leases", "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r470", "r579" ] }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FinanceLeaseRightOfUseAssetAmortization", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureLeasesLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Right-of-Use Asset, Amortization", "terseLabel": "Amortization of lease assets", "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease." } } }, "auth_ref": [ "r462", "r466", "r579" ] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Principal Payments", "negatedLabel": "Repayments of principal under finance lease", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": [ "r463", "r468" ] }, "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FederalIncomeTaxExpenseBenefitContinuingOperations", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Federal Income Tax Expense (Benefit), Continuing Operations", "negatedLabel": "Income tax (expense) benefit", "documentation": "Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r217", "r404" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "terseLabel": "Schedule of RSU activity", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [ "r110" ] }, "us-gaap_FinanceLeaseInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FinanceLeaseInterestExpense", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureLeasesLeaseCostDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Interest Expense", "terseLabel": "Interest on lease liabilities", "documentation": "Amount of interest expense on finance lease liability." } } }, "auth_ref": [ "r462", "r466", "r579" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, Payments, Due Year Two", "terseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r473" ] }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, Current", "terseLabel": "Finance lease liability, current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": [ "r461" ] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Financing lease liability, net of current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": [ "r461" ] }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average incremental borrowing rate, Finance leases", "documentation": "Weighted average discount rate for finance lease calculated at point in time." } } }, "auth_ref": [ "r471", "r579" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, Payments, Due Next Twelve Months", "terseLabel": "2024", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r473" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "2023 (excluding the nine months ended September 30, 2023)", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r641" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureLeasesScheduleOfOperatingLeaseLiabilitiesMaturitiesDetailsCalc2": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, Payment, Due", "totalLabel": "Total minimum lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r473" ] }, "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Other Current Assets [Table Text Block]", "terseLabel": "Schedule of prepaid expenses and other current assets", "documentation": "Tabular disclosure of the carrying amounts of other current assets." } } }, "auth_ref": [] }, "us-gaap_StockGrantedDuringPeriodValueSharebasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StockGrantedDuringPeriodValueSharebasedCompensation", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Stock based compensation", "documentation": "Value, after forfeiture, of shares granted under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r107", "r119" ] }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureLeasesScheduleOfOperatingLeaseLiabilitiesMaturitiesDetailsCalc2": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: imputed interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r473" ] }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Assets Acquired and Liabilities Assumed in Acquisition", "terseLabel": "Schedule of purchase price allocation", "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree." } } }, "auth_ref": [ "r130" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, Payments, Due Year Three", "terseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r473" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of stock option valuation assumptions", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r117" ] }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Maturities of finance lease liabilities" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FinanceLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesFacilityLeaseDetails", "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization", "terseLabel": "Finance lease right-of-use asset", "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": [ "r460" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of stock option activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r110", "r114", "r115" ] }, "us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ContractWithCustomerReceivableAfterAllowanceForCreditLossCurrent", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Contract with customer, receivable, after allowance for credit loss, current", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional, classified as current." } } }, "auth_ref": [ "r341", "r344", "r356" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue, current portion", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r341", "r342", "r356" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "UseOfEstimates", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r77", "r78", "r79", "r250", "r251", "r252", "r253" ] }, "us-gaap_VehiclesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "VehiclesMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosurePropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Vehicles", "terseLabel": "Vehicles", "documentation": "Equipment used primarily for road transportation." } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Operating loss", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r258", "r266", "r270", "r272", "r559" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other expense (income), net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r56" ] }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Deferred revenue, net of current portion", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r341", "r342", "r356" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureNetLossPerShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of reconciliation of net loss", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r608" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of fair value of financial instruments measured on a recurring basis", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r444", "r445" ] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability", "terseLabel": "Customer deposits", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r341", "r342", "r356" ] }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Sale of Property, Plant, and Equipment", "verboseLabel": "Disposal of property and equipment", "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r57" ] }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ContractWithCustomerAssetNetCurrent", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current", "terseLabel": "Contract assets", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current." } } }, "auth_ref": [ "r341", "r343", "r356" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureAccruedExpensesAndOtherLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAccruedExpensesAndOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Other expenses", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r35" ] }, "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]", "terseLabel": "Schedule of carrying amount of goodwill and intangible assets", "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class." } } }, "auth_ref": [ "r83" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "WarrantMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWarrantWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Warrant", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosureRevenueDetails", "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Revenue From Contract With Customer, Including Assessed Tax", "verboseLabel": "Revenue", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": [ "r254", "r255", "r265", "r268", "r269", "r273", "r274", "r276", "r354", "r355", "r506" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AmendmentFlag", "presentation": [ "http://www.nighthawkbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r33", "r580" ] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Basis of Presentation and Significant Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsCarryingAmountOfGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r85", "r87", "r507" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.nighthawkbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityShellCompany", "presentation": [ "http://www.nighthawkbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r585" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r273", "r506", "r567", "r581", "r622", "r623", "r628", "r653" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesFacilityLeaseDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "auth_ref": [ "r274", "r275", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r568", "r582", "r628" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Unrealized gain on foreign currency translation", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r41" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityFilerCategory", "presentation": [ "http://www.nighthawkbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r585" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntitySmallBusiness", "presentation": [ "http://www.nighthawkbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r585" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive income", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r47", "r103", "r199", "r202", "r207", "r453", "r458", "r459", "r511", "r519", "r598", "r599" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.nighthawkbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r585" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit)", "terseLabel": "Income tax expense (benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r219", "r234", "r235", "r257", "r404", "r418", "r421", "r524" ] }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAccruedExpensesAndOtherLiabilities" ], "lang": { "en-us": { "role": { "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "terseLabel": "Accrued Expenses and Other Liabilities", "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period." } } }, "auth_ref": [] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShortTermInvestments", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Short-term Investments", "terseLabel": "Short-term investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": [ "r161", "r162", "r168", "r596" ] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Assets:" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r70" ] }, "us-gaap_DepositsAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DepositsAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deposits Assets, Noncurrent", "terseLabel": "Deposits", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r592" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityAccountingForStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Expiration term", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r576" ] }, "us-gaap_ShortTermInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShortTermInvestmentsAbstract", "lang": { "en-us": { "role": { "label": "Short-Term Investments." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Sale, Maturity and Collection of Short-term Investments", "terseLabel": "Sale of short-term investments", "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term." } } }, "auth_ref": [ "r58" ] }, "us-gaap_LeaseCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LeaseCostAbstract", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Finance lease cost" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r60" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r76" ] }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_EarningsPerShareDiluted", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureNetLossPerShareReconciliationOfNetLossDetails", "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "terseLabel": "Net loss per share, diluted - continuing operations (in dollars per share)", "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r48", "r175", "r178", "r211", "r226", "r228", "r229", "r230", "r231", "r239", "r241", "r242", "r243", "r443", "r515", "r523" ] }, "nhwk_RevenueEarnOutMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "RevenueEarnOutMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfInputsAndValuationMethodologiesUsedDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Revenue Earn Out.", "label": "Revenue earn-out" } } }, "auth_ref": [] }, "nhwk_ContractDeferredConsiderationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "ContractDeferredConsiderationMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfInputsAndValuationMethodologiesUsedDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to contingent consideration.", "label": "Deferred contract consideration" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "totalLabel": "Total non-operating loss", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r55" ] }, "nhwk_BusinessCombinationReceivableConsiderationPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "BusinessCombinationReceivableConsiderationPaid", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of receivable consideration paid during the period.", "label": "Business Combination, Receivable Consideration Paid", "terseLabel": "Consideration paid" } } }, "auth_ref": [] }, "nhwk_OperatingLeaseReimbursementOfExpensesCapitalized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "OperatingLeaseReimbursementOfExpensesCapitalized", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesFacilityLeaseDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of expenses reimbursed in operating lease which is capitalized.", "label": "Operating Lease, Reimbursement of Expenses, Capitalized", "terseLabel": "Reimbursement of expenses, capitalized" } } }, "auth_ref": [] }, "nhwk_NumberOfVialsToBeDelivered": { "xbrltype": "integerItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "NumberOfVialsToBeDelivered", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of vials to be delivered.", "label": "Number of Vials to be Delivered", "terseLabel": "Number of vials to be delivered" } } }, "auth_ref": [] }, "nhwk_AccountsReceivableCurrentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "AccountsReceivableCurrentMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing accounts receivable current.", "label": "Accounts Receivable, Current [Member]", "terseLabel": "Accounts receivable" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityChangesInOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Warrants to purchase common stock", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r339" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureNetLossPerShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of potentially dilutive securities", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r76" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureCommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "verboseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r101", "r307", "r308", "r533", "r624" ] }, "nhwk_AnthimVialsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "AnthimVialsMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to vials of ANTHIM.", "label": "ANTHIM Vials" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAccruedExpensesAndOtherLiabilitiesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses and other liabilities", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfDiscontinuedOperationInOperationsStatementDetails" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Net loss from discontinued operations", "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r4", "r5", "r6", "r7", "r8", "r20", "r176", "r187", "r423" ] }, "nhwk_OperatingLeaseReimbursementsExpensed": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "OperatingLeaseReimbursementsExpensed", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesFacilityLeaseDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of expenses reimbursed in operating lease which is expensed.", "label": "Operating Lease, Reimbursements, Expensed", "terseLabel": "Reimbursements, expensed" } } }, "auth_ref": [] }, "nhwk_AssetsTransferFromLevel1ToLevel2TransfersAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "AssetsTransferFromLevel1ToLevel2TransfersAmount1", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWarrantWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.", "label": "Assets transfer from level 1 to level 2 Transfers Amount1", "terseLabel": "Assets transfer from level 1 to level 2" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total Current Liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r36", "r189", "r216", "r286", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r434", "r437", "r438", "r452", "r580", "r625", "r643", "r644" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Estimated fair value", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r81", "r282", "r293", "r510" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current Liabilities" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfAssetsAndLiabilitiesClassifiedAsHeldForSaleInConsolidatedBalanceSheetsDetails", "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfDiscontinuedOperationInOperationsStatementDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r1", "r9", "r10", "r11", "r12", "r14", "r15", "r19", "r21", "r22", "r23", "r98", "r99" ] }, "nhwk_BusinessAcquisitionAnnualizedEarnOutPaymentsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "BusinessAcquisitionAnnualizedEarnOutPaymentsPercentage", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of earn out payments during each year as a part of business combination.", "label": "Business Acquisition, Annualized Earn Out Payments Percentage", "terseLabel": "Percentage of earn out payments" } } }, "auth_ref": [] }, "nhwk_BusinessAcquisitionEarnOutPaymentsPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "BusinessAcquisitionEarnOutPaymentsPeriod", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Earn out payments period in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Business Acquisition, Earn Out Payments Period", "terseLabel": "Earn out payments period" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CommonStockMember", "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r604", "r605", "r634" ] }, "nhwk_BusinessAcquisitionPeriodOfOccurrenceOfEarnOutPayment": { "xbrltype": "durationItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "BusinessAcquisitionPeriodOfOccurrenceOfEarnOutPayment", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Period when earn payment occurs, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Business Acquisition, Period of Occurrence of Earn Out Payment", "terseLabel": "Period of occurrence of earn payment" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureIncomeTax" ], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Tax", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r218", "r406", "r410", "r413", "r417", "r420", "r424", "r425", "r426" ] }, "nhwk_BusinessAcquisitionFrequencyOfPeriodicEarnOutPayment": { "xbrltype": "durationItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "BusinessAcquisitionFrequencyOfPeriodicEarnOutPayment", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Frequency occurrence of periodic (monthly, quarterly, annual) earn payment, \nin 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Business Acquisition, Frequency of Periodic Earn Out Payment", "terseLabel": "Frequency of periodic earn out payment" } } }, "auth_ref": [] }, "nhwk_WarrantLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "WarrantLiabilityMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsChangeInFairValueDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to warrant liabilities.", "label": "Warrant Liability" } } }, "auth_ref": [] }, "nhwk_ElusysTherapeuticsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "ElusysTherapeuticsMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsComponentsOfPurchaseConsiderationDetails", "http://www.nighthawkbio.com/role/DisclosureAcquisitionsNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails", "http://www.nighthawkbio.com/role/DisclosureAcquisitionsTables", "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsChangeInFairValueDetails", "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfInputsAndValuationMethodologiesUsedDetails", "http://www.nighthawkbio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsCarryingAmountOfGoodwillAndIntangibleAssetsDetails", "http://www.nighthawkbio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsDetails", "http://www.nighthawkbio.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Elusys Therapeutics.", "label": "Elusys Therapeutics", "terseLabel": "Elusys Therapeutics" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PaymentsToAcquireShortTermInvestments", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Short-term Investments", "negatedLabel": "Purchase of short-term investments", "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term." } } }, "auth_ref": [ "r62" ] }, "nhwk_BusinessCombinationConsiderationTransferredFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "BusinessCombinationConsiderationTransferredFairValue", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Fair value of amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred, Fair Value", "terseLabel": "Fair value of the purchase consideration" } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": [ "r149", "r150" ] }, "nhwk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPreliminaryPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of operating lease right of use assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease, Right of Use Assets", "terseLabel": "Operating lease right of use assets" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfAssetsAndLiabilitiesClassifiedAsHeldForSaleInConsolidatedBalanceSheetsDetails", "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfDiscontinuedOperationInOperationsStatementDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Discontinued Operations", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "nhwk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContractReceivables", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPreliminaryPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of contract receivables recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contract Receivables", "terseLabel": "Contract receivables" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "EquityComponentDomain", "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r103", "r184", "r204", "r205", "r206", "r223", "r224", "r225", "r227", "r233", "r235", "r249", "r287", "r340", "r398", "r399", "r400", "r415", "r416", "r441", "r453", "r454", "r455", "r456", "r457", "r459", "r474", "r526", "r527", "r528" ] }, "nhwk_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedAccruedLiabilitiesAndOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedAccruedLiabilitiesAndOtherCurrentLiabilities", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPreliminaryPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of accrued liabilities and other current liabilities assumed in business combination.", "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Accrued Liabilities And Other Current Liabilities", "negatedLabel": "Accrued expenses and other current liabilities" } } }, "auth_ref": [] }, "nhwk_ContingentConsiderationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "ContingentConsiderationMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsChangeInFairValueDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to contingent consideration.", "label": "Contingent Consideration" } } }, "auth_ref": [] }, "nhwk_BusinessCombinationDeferredContingentPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "BusinessCombinationDeferredContingentPayment", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureAcquisitionsComponentsOfPurchaseConsiderationDetails": { "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsComponentsOfPurchaseConsiderationDetails", "http://www.nighthawkbio.com/role/DisclosureAcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of deferred contingent payment under business combination.", "label": "Business Combination, Deferred Contingent Payment", "terseLabel": "Deferred cash consideration" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWarrantWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Class Of Warrant Or Right Outstanding", "terseLabel": "Warrants outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "nhwk_BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "BusinessCombinationRecognizedIdentifiableAssetAcquiredAndLiabilityAssumedOperatingLeaseObligations", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPreliminaryPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of operating lease obligation classified in business combination.", "label": "Business Combination, Recognized Identifiable Asset Acquired and Liability Assumed, Operating Lease Obligations", "negatedLabel": "Operating lease obligations" } } }, "auth_ref": [] }, "nhwk_BusinessCombinationGoodwillTaxDeductiblePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "BusinessCombinationGoodwillTaxDeductiblePeriod", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The period for which the goodwill arising from business combination will be deductible for tax purposes.", "label": "Business Combination, Goodwill Tax Deductible, Period", "terseLabel": "Goodwill deductible for tax purposes" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfAssetsAndLiabilitiesClassifiedAsHeldForSaleInConsolidatedBalanceSheetsDetails", "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfDiscontinuedOperationInOperationsStatementDetails", "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r572", "r573" ] }, "nhwk_BusinessCombinationEarnOutConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "BusinessCombinationEarnOutConsideration", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureAcquisitionsComponentsOfPurchaseConsiderationDetails": { "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsComponentsOfPurchaseConsiderationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of consideration in the form of earn out payments arising from business combination.", "label": "Business Combination, Earn Out Consideration", "terseLabel": "Earn out" } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "nhwk_BusinessCombinationAdditionalEarnOutConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "BusinessCombinationAdditionalEarnOutConsideration", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureAcquisitionsComponentsOfPurchaseConsiderationDetails": { "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsComponentsOfPurchaseConsiderationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of consideration in the form of additional earn out payments arising from business combination.", "label": "Business Combination, Additional Earn Out Consideration", "terseLabel": "Additional earn out" } } }, "auth_ref": [] }, "nhwk_BusinessCombinationReceivableConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "BusinessCombinationReceivableConsideration", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureAcquisitionsComponentsOfPurchaseConsiderationDetails": { "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsComponentsOfPurchaseConsiderationDetails", "http://www.nighthawkbio.com/role/DisclosureAcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of receivable consideration arising from business combination.", "label": "Business Combination, Receivable Consideration", "terseLabel": "Receivable consideration" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityChangesInOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Exercise price of warrants", "terseLabel": "Weighted-average exercise price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r339" ] }, "nhwk_BusinessCombinationContractDeferredConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "BusinessCombinationContractDeferredConsideration", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureAcquisitionsComponentsOfPurchaseConsiderationDetails": { "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsComponentsOfPurchaseConsiderationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of contract deferred consideration arising from business combination.", "label": "Business Combination, Contract Deferred Consideration", "terseLabel": "Contract deferred consideration" } } }, "auth_ref": [] }, "nhwk_BusinessCombinationPreliminaryEstimatedFairValueOfContingentAndDeferredConsiderationLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "BusinessCombinationPreliminaryEstimatedFairValueOfContingentAndDeferredConsiderationLiabilities", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The preliminary estimated fair value of the contingent and deferred consideration liabilities related to the receivable consideration, contract deferred consideration, earn out and additional earn out payments arising from business combination.", "label": "Business Combination, Preliminary Estimated Fair Value Of Contingent And Deferred Consideration Liabilities", "terseLabel": "Fair value of contingent and deferred consideration liabilities" } } }, "auth_ref": [] }, "nhwk_BusinessCombinationDiscountRateForDeferredConsideration": { "xbrltype": "percentItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "BusinessCombinationDiscountRateForDeferredConsideration", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The discount rate used in the preliminary valuation of deferred consideration arising from business combination.", "label": "Business Combination, Discount Rate For Deferred Consideration", "verboseLabel": "Discount rate for deferred consideration" } } }, "auth_ref": [] }, "nhwk_BusinessCombinationDiscountRateForEarnOutLiabilities": { "xbrltype": "percentItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "BusinessCombinationDiscountRateForEarnOutLiabilities", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The discount rate used in the preliminary valuation of earn out liabilities arising from business combination.", "label": "Business Combination, Discount Rate For Earn Out Liabilities", "terseLabel": "Discount rate for earn out liabilities" } } }, "auth_ref": [] }, "nhwk_BusinessCombinationAdditionalEarnOutLiabilitiesAsPercentageOfGrossSalePrice": { "xbrltype": "percentItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "BusinessCombinationAdditionalEarnOutLiabilitiesAsPercentageOfGrossSalePrice", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The additional earn out liabilities calculated as a percentage of gross sale price under business combination.", "label": "Business Combination, Additional Earn Out Liabilities As A Percentage Of Gross Sale Price", "terseLabel": "Preliminary value of Additional Earn Out liability as percentage" } } }, "auth_ref": [] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfAssetsAndLiabilitiesClassifiedAsHeldForSaleInConsolidatedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Assets", "totalLabel": "Total assets held for sale", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r0", "r1", "r18", "r97", "r186", "r187" ] }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Purchases of property and equipment included in accounts payable", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred." } } }, "auth_ref": [ "r71", "r72", "r73" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityAccountingForStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Amount Capitalized", "terseLabel": "Compensation expenses capitalized", "documentation": "Amount of cost capitalized for award under share-based payment arrangement." } } }, "auth_ref": [ "r396" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r27" ] }, "nhwk_LicenseRevenueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "LicenseRevenueAbstract", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "N/A", "label": "License Revenue [Abstract]", "terseLabel": "License Revenue" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesFacilityLeaseDetails", "http://www.nighthawkbio.com/role/DisclosurePropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Type [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r94" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.0002 par value; 250,000,000 shares authorized, 26,081,890 and 25,661,488 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r27", "r580" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized stock-based compensation expense", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r631" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureAccruedExpensesAndOtherLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAccruedExpensesAndOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Compensation and related benefits", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r35" ] }, "us-gaap_MutualFundMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "MutualFundMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Mutual funds", "documentation": "Regulated investment instrument that pools funds from multiple investors to invest principally in a portfolio of securities and money market instruments to match the investment objective." } } }, "auth_ref": [ "r630" ] }, "us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CashCashEquivalentsAndShortTermInvestmentsTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureShortTermInvestments" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, and Short-term Investments [Text Block]", "terseLabel": "Short-Term Investments", "documentation": "The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities." } } }, "auth_ref": [ "r82" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r27" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash and cash equivalents", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r638" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of revenues", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r53", "r506" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r610", "r642" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentType", "presentation": [ "http://www.nighthawkbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r27", "r103" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Federal corporate tax rate", "verboseLabel": "Statutory federal tax rate", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r218", "r405", "r419" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r27" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and Cash Equivalents - End of the Period", "periodStartLabel": "Cash and Cash Equivalents - Beginning of the Period", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r64", "r69", "r74" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsCarryingAmountOfGoodwillAndIntangibleAssetsDetails", "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Amortization of Intangible Assets", "negatedLabel": "Amortization of intangible asset", "terseLabel": "Amortization of intangible asset", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r67", "r84", "r89" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (Decrease) Increase in Cash and Cash Equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r64", "r156" ] }, "us-gaap_DeferredRevenueArrangementByTypeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DeferredRevenueArrangementByTypeTable", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Revenue Arrangement, by Type [Table]", "documentation": "Schedule of deferred revenue disclosure which includes the type of arrangements and the corresponding amount that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Stockholders' Equity" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsComponentsOfPurchaseConsiderationDetails", "http://www.nighthawkbio.com/role/DisclosureAcquisitionsNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails", "http://www.nighthawkbio.com/role/DisclosureAcquisitionsTables", "http://www.nighthawkbio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities." } } }, "auth_ref": [ "r126", "r127", "r429" ] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfAssetsAndLiabilitiesClassifiedAsHeldForSaleInConsolidatedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "InvestmentPolicyTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Investment, Policy [Policy Text Block]", "verboseLabel": "Short-term Investments", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": [ "r285", "r652" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityChangesInOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number", "periodEndLabel": "Outstanding, ending balance", "periodStartLabel": "Outstanding, beginning balance", "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments." } } }, "auth_ref": [ "r111", "r112" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Restricted stock granted", "verboseLabel": "Granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r377" ] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfAssetsAndLiabilitiesClassifiedAsHeldForSaleInConsolidatedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Liabilities", "totalLabel": "Total liabilities held for sale", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r0", "r1", "r18", "r97", "r186", "r187" ] }, "us-gaap_OtherCurrentAssetsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "OtherCurrentAssetsTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" ], "lang": { "en-us": { "role": { "label": "Other Current Assets [Text Block]", "terseLabel": "Prepaid Expenses and Other Current Assets", "documentation": "The entire disclosure for other current assets." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "MaximumMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.nighthawkbio.com/role/DisclosureRevenueDetails", "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityAccountingForStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Maximum", "terseLabel": "Maximum" } } }, "auth_ref": [ "r309", "r310", "r311", "r312", "r366", "r505", "r525", "r546", "r547", "r566", "r574", "r583", "r627", "r645", "r646", "r647", "r648", "r649", "r650" ] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfAssetsAndLiabilitiesClassifiedAsHeldForSaleInConsolidatedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent [Abstract]", "terseLabel": "Long term liabilities:" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "MinimumMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosurePropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Minimum", "terseLabel": "Minimum" } } }, "auth_ref": [ "r309", "r310", "r311", "r312", "r366", "r505", "r525", "r546", "r547", "r566", "r574", "r583", "r627", "r645", "r646", "r647", "r648", "r649", "r650" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price", "terseLabel": "Expired (in dollars per share)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } }, "auth_ref": [ "r380" ] }, "us-gaap_MarketableSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "MarketableSecuritiesCurrent", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Marketable Securities, Current", "terseLabel": "Short-term investments", "documentation": "Amount of investment in marketable security, classified as current." } } }, "auth_ref": [] }, "nhwk_ProcessDevelopmentContractLiabilityReclassificationToRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "ProcessDevelopmentContractLiabilityReclassificationToRevenue", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of process development contract liability reclassified to revenue as a result of performance obligations satisfied.", "label": "Process Development Contract Liability, Reclassification To Revenue", "terseLabel": "Reclassification to revenue as the result of performance obligations satisfied" } } }, "auth_ref": [] }, "us-gaap_DeferredRevenueArrangementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DeferredRevenueArrangementLineItems", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Revenue Arrangement [Line Items]", "terseLabel": "Grant Revenue", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Stockholders' Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r32", "r160", "r172", "r580", "r603", "r614", "r637" ] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureAcquisitionsComponentsOfPurchaseConsiderationDetails": { "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsComponentsOfPurchaseConsiderationDetails", "http://www.nighthawkbio.com/role/DisclosureAcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Cash consideration", "terseLabel": "Cash consideration", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r59", "r431" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r34", "r216", "r286", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r434", "r437", "r438", "r452", "r558", "r625", "r643", "r644" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized stock-based compensation expense, recognition period", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r397" ] }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsTables" ], "lang": { "en-us": { "role": { "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Schedule of Assets, liabilities and operations classified as held for sale", "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r1", "r9", "r10", "r11", "r12", "r14", "r15", "r19", "r21", "r22", "r23", "r98", "r99" ] }, "nhwk_CostOfRevenuesAndSellingGeneralAndAdministrativeExpensePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "CostOfRevenuesAndSellingGeneralAndAdministrativeExpensePolicyPolicyTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cost of revenues and selling, general and administrative expense.", "label": "Cost Of Revenues And Selling, General And Administrative Expense, Policy [Policy Text Block]", "terseLabel": "Cost of revenues and selling, general and administrative expense" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Exercise Price" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfAssetsAndLiabilitiesClassifiedAsHeldForSaleInConsolidatedBalanceSheetsDetails", "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current", "terseLabel": "Current liabilities held for sale", "totalLabel": "Total current liabilities", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r0", "r1", "r18", "r92", "r97", "r186", "r187" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityRestrictedStockDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Shares", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityRestrictedStockDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Restricted stock at end of period", "periodStartLabel": "Restricted stock at beginning of period", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r381", "r382" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Acquisition of Elusys Therapeutics, net of cash paid", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r59" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityRestrictedStockDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r384" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails", "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityAccountingForStockBasedCompensationDetails" ], "lang": { "en-us": { "role": { "label": "Employee stock options", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long Term Liabilities" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r405" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityAccountingForStockBasedCompensationDetails", "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityChangesInOutstandingWarrantsDetails", "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityRestrictedStockDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Stockholders' Equity", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "nhwk_NumberOfCustomersRevenueDerivedFrom": { "xbrltype": "integerItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "NumberOfCustomersRevenueDerivedFrom", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of customers revenue was derived from.", "label": "Number Of Customers Revenue Derived From", "terseLabel": "Number of customers process development revenue was derived from" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.nighthawkbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Presentation and Principles of Consolidation", "terseLabel": "Basis of Presentation and Principles of Consolidation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsMiscellaneousNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "OtherAssetsMiscellaneousNoncurrent", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Assets, Miscellaneous, Noncurrent", "terseLabel": "Other assets", "documentation": "Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityRestrictedStockDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Restricted stock at end of period", "periodStartLabel": "Restricted stock at beginning of period", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r381", "r382" ] }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Goodwill and Intangible Assets", "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets." } } }, "auth_ref": [ "r83", "r86" ] }, "us-gaap_AccruedLiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AccruedLiabilitiesCurrentAbstract", "lang": { "en-us": { "role": { "label": "Accrued Expenses and Other Liabilities" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesFacilityLeaseDetails", "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r460" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityAccountingForStockBasedCompensationDetails", "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r66" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityRestrictedStockDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r384" ] }, "us-gaap_GoodwillAcquiredDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Goodwill Acquired During Period", "terseLabel": "Goodwill acquired", "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination." } } }, "auth_ref": [ "r299", "r563" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesFacilityLeaseDetails", "http://www.nighthawkbio.com/role/DisclosurePropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Type [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r96" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Payments", "terseLabel": "Operating lease payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r464", "r468" ] }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "GoodwillPurchaseAccountingAdjustments", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsCarryingAmountOfGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Goodwill, Purchase Accounting Adjustments", "verboseLabel": "Acquisition fair value adjustments", "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r123", "r617" ] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Statements of Operations and Comprehensive Loss" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property and Equipment" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosurePropertyAndEquipmentTables" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of property and equipment", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r96" ] }, "us-gaap_GoodwillPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "GoodwillPeriodIncreaseDecrease", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Goodwill, Period Increase (Decrease)", "terseLabel": "Increase in goodwill", "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r619" ] }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FinitelivedIntangibleAssetsAcquired1", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-lived Intangible Assets Acquired", "terseLabel": "Finite-lived intangible assets acquired", "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition." } } }, "auth_ref": [ "r303" ] }, "us-gaap_AccruedMarketingCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AccruedMarketingCostsCurrent", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureAccruedExpensesAndOtherLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAccruedExpensesAndOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Marketing Costs, Current", "terseLabel": "Accrued marketing expenses", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Remaining Contractual Life", "terseLabel": "Aggregate Intrinsic Value" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Balance Sheets" } } }, "auth_ref": [] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsCarryingAmountOfGoodwillAndIntangibleAssetsDetails", "http://www.nighthawkbio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsDetails", "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Goodwill, Impairment Loss", "negatedLabel": "Impairment", "terseLabel": "Goodwill impairment loss", "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r67", "r298", "r300", "r301", "r563" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r38", "r103", "r184", "r204", "r205", "r206", "r223", "r224", "r225", "r227", "r233", "r235", "r249", "r287", "r340", "r398", "r399", "r400", "r415", "r416", "r441", "r453", "r454", "r455", "r456", "r457", "r459", "r474", "r526", "r527", "r528" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "verboseLabel": "Forfeited", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r379" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Stock options exercisable at end of period", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r375" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StatementLineItems", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueFinancialInstrumentsDetails", "http://www.nighthawkbio.com/role/DisclosureShortTermInvestmentsDetails", "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "Basis of Presentation and Significant Accounting Policies", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "label": "Operating lease costs", "terseLabel": "Operating lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r467", "r579" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureGoodwillAndOtherIntangibleAssets" ], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Goodwill and Other Intangible Assets", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r90" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StatementTable", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueFinancialInstrumentsDetails", "http://www.nighthawkbio.com/role/DisclosureShortTermInvestmentsDetails", "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r223", "r224", "r225", "r249", "r506" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Stock options exercisable", "terseLabel": "Stock options exercisable at end of period", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r375" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.nighthawkbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Statements of Cash Flows" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityAccountingForStockBasedCompensationDetails", "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityRestrictedStockDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r575" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityStockOptionValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Expected volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r392" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityStockOptionValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Risk-free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r394" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityStockOptionValuationAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Dividend yield.", "verboseLabel": "Dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r393" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.nighthawkbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPreliminaryPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails", "http://www.nighthawkbio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsCarryingAmountOfGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Goodwill", "periodEndLabel": "Goodwill ending balance", "periodStartLabel": "Goodwill beginning balance", "terseLabel": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r193", "r297", "r509", "r563", "r580", "r616", "r618" ] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfAssetsAndLiabilitiesClassifiedAsHeldForSaleInConsolidatedBalanceSheetsDetails", "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent", "terseLabel": "Non-current liabilities held for sale", "totalLabel": "Total long term liabilities", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r0", "r1", "r18", "r91", "r97", "r186", "r187" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Stock options outstanding at end of period", "periodStartLabel": "Stock options outstanding at beginning of period", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r118" ] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "GoodwillRollForward", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsCarryingAmountOfGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityRestrictedStockDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Fair Value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityChangesInOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations", "negatedLabel": "Expired", "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed." } } }, "auth_ref": [ "r113" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Other Intangible Assets" } } }, "auth_ref": [] }, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Contract award", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": [ "r351" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://www.nighthawkbio.com/role/DisclosurePropertyAndEquipmentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosurePropertyAndEquipmentDetails", "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and Equipment, net", "totalLabel": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r96", "r173", "r517", "r580" ] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Consolidated Statements of Stockholders' Equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LiabilitiesFairValueDisclosureAbstract", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Liabilities:" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/DisclosurePropertyAndEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosurePropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Total", "terseLabel": "Total", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r94", "r191" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Outstanding stock options", "periodEndLabel": "Stock options outstanding at end of period", "periodStartLabel": "Stock options outstanding at beginning of period", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r373", "r374" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Reconciliation of cash and cash equivalents at September 30, 2023 and 2022" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CityAreaCode", "presentation": [ "http://www.nighthawkbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r69", "r190", "r548" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Stock options outstanding at end of period (in dollars per share)", "periodStartLabel": "Stock options outstanding at beginning of period (in dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r373", "r374" ] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfAssetsAndLiabilitiesClassifiedAsHeldForSaleInConsolidatedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "label": "Liabilities held for sale:" } } }, "auth_ref": [] }, "nhwk_InitialLicenseFeesReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "InitialLicenseFeesReceived", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Cash inflow due to receipt of initial license fees.", "label": "Initial License Fees Received", "terseLabel": "Initial license fees received" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "BusinessAcquisitionsProFormaRevenue", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsSupplementalProFormaFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Pro Forma Revenue", "terseLabel": "Revenue", "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period." } } }, "auth_ref": [ "r427", "r428" ] }, "nhwk_OtherAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "OtherAssetsPolicyTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for other assets.", "label": "Other Assets [Policy Text Block]", "terseLabel": "Other Assets" } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.nighthawkbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "nhwk_LeaseLiabilityToBePaidAfterYearSix": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "LeaseLiabilityToBePaidAfterYearSix", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": { "parentTag": "nhwk_LeaseLiabilityPaymentDue", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after sixth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lease, Liability, to be Paid, after Year Six", "terseLabel": "Thereafter" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r302", "r304", "r305", "r306", "r507", "r508" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 }, "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureNetLossPerShareReconciliationOfNetLossDetails", "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "totalLabel": "Net loss", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r187", "r198", "r201", "r212", "r216", "r226", "r234", "r235", "r258", "r266", "r270", "r272", "r286", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r432", "r435", "r436", "r443", "r452", "r516", "r559", "r577", "r578", "r600", "r625" ] }, "nhwk_LeaseLiabilityToBePaidYearSix": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "LeaseLiabilityToBePaidYearSix", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": { "parentTag": "nhwk_LeaseLiabilityPaymentDue", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for lease to be paid in sixth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lease, Liability, to be Paid, Year Six", "terseLabel": "2029" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsCarryingAmountOfGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Goodwill and Intangible Assets", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ValuationTechniqueDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ValuationTechniqueDomain", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfInputsAndValuationMethodologiesUsedDetails" ], "lang": { "en-us": { "role": { "label": "Valuation Approach and Technique [Domain]", "documentation": "Valuation approach and technique." } } }, "auth_ref": [ "r152" ] }, "nhwk_FinanceLeaseLiabilityToBePaidAfterYearSix": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "FinanceLeaseLiabilityToBePaidAfterYearSix", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after sixth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, after Year Six", "terseLabel": "Thereafter" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.nighthawkbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "BusinessCombinationDisclosureTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitions" ], "lang": { "en-us": { "role": { "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Acquisitions", "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)." } } }, "auth_ref": [ "r134", "r430" ] }, "us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FiniteLivedIntangibleAssetsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-lived Intangible Assets, Fair Value Disclosure", "terseLabel": "Intangible assets fair value", "documentation": "Fair value portion of assets, excluding financial assets, that lack physical substance, having a limited useful life." } } }, "auth_ref": [ "r635" ] }, "nhwk_LesseeOperatingLeaseLiabilityToBePaidAfterYearSix": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearSix", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after sixth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Six", "terseLabel": "Thereafter" } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Category of Item Purchased [Axis]", "documentation": "Information by category of items purchased under a long-term purchase commitment." } } }, "auth_ref": [] }, "nhwk_LesseeOperatingLeaseSubsequentRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "LesseeOperatingLeaseSubsequentRenewalTerm", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesFacilityLeaseDetails" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, subsequent to the expiration of initial lease term.", "label": "Lessee Operating Lease Subsequent Renewal Term", "terseLabel": "Lease subsequent renewal term" } } }, "auth_ref": [] }, "nhwk_FinanceLeaseLiabilityToBePaidYearSix": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "FinanceLeaseLiabilityToBePaidYearSix", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in sixth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Six", "terseLabel": "2029" } } }, "auth_ref": [] }, "nhwk_LesseeOperatingLeaseLiabilityToBePaidYearSix": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "LesseeOperatingLeaseLiabilityToBePaidYearSix", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in sixth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Six", "terseLabel": "2029" } } }, "auth_ref": [] }, "us-gaap_ValuationTechniqueDiscountedCashFlowMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ValuationTechniqueDiscountedCashFlowMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfInputsAndValuationMethodologiesUsedDetails" ], "lang": { "en-us": { "role": { "label": "Discounted cash flow analysis", "documentation": "Valuation technique calculating present value of future cash flows." } } }, "auth_ref": [ "r636" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsComponentsOfPurchaseConsiderationDetails", "http://www.nighthawkbio.com/role/DisclosureAcquisitionsNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails", "http://www.nighthawkbio.com/role/DisclosureAcquisitionsTables", "http://www.nighthawkbio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Line Items]", "terseLabel": "Goodwill and other intangible assets", "verboseLabel": "Acquisitions", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ValuationTechniqueAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ValuationTechniqueAxis", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfInputsAndValuationMethodologiesUsedDetails" ], "lang": { "en-us": { "role": { "label": "Valuation Approach and Technique [Axis]", "documentation": "Information by valuation approach and technique." } } }, "auth_ref": [ "r152" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "label": "Lease liabilities weighted-average discount rate", "terseLabel": "Weighted average incremental borrowing rate, Operating leases", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r471", "r579" ] }, "nhwk_AmountOfMatchForEveryDollarOfGrant": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "AmountOfMatchForEveryDollarOfGrant", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount the company is required to match of each dollar of grant.", "label": "Amount Of Match For Every Dollar Of Grant", "terseLabel": "Amount the company is required to match of each dollar of grant" } } }, "auth_ref": [] }, "nhwk_ThresholdAmountForMatchOfGrant": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "ThresholdAmountForMatchOfGrant", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Threshold amount for match of grant.", "label": "Threshold Amount For Match Of Grant", "terseLabel": "Threshold amount for match of grant" } } }, "auth_ref": [] }, "nhwk_WarrantsReclassifiedToLiability": { "xbrltype": "sharesItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "WarrantsReclassifiedToLiability", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWarrantWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants reclassified to liability.", "label": "Warrants Reclassified To Liability", "terseLabel": "Number of warrants reclassified to liability" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "label": "Lease weighted-average life", "terseLabel": "Weighted average remaining lease term (years), Operating leases", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r470", "r579" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.nighthawkbio.com/role/DisclosurePropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r96" ] }, "nhwk_RemainingLeaseTermAndIncrementalBorrowingRateTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "RemainingLeaseTermAndIncrementalBorrowingRateTableTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the weighted average remaining lease term and incremental borrowing rate.", "label": "Remaining Lease Term And Incremental Borrowing Rate [Table Text Block]", "terseLabel": "Schedule of weighted average remaining lease term and incremental borrowing rate" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.nighthawkbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "nhwk_AccruedManufacturingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "AccruedManufacturingExpenses", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureAccruedExpensesAndOtherLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAccruedExpensesAndOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for manufacturing expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Manufacturing Expenses", "terseLabel": "Accrued manufacturing expenses" } } }, "auth_ref": [] }, "nhwk_PrepaidPreclinicalAndClinicalExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "PrepaidPreclinicalAndClinicalExpenses", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for preclinical and clinical expenses", "label": "Prepaid Preclinical And Clinical Expenses", "terseLabel": "Prepaid preclinical and clinical expenses" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.nighthawkbio.com/role/DisclosurePropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Estimated useful lives", "terseLabel": "Estimated useful lives", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsCarryingAmountOfGoodwillAndIntangibleAssetsDetails", "http://www.nighthawkbio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net", "periodEndLabel": "Intangible assets, ending balance", "periodStartLabel": "Intangible assets beginning balance", "terseLabel": "Balance of finite-lived intangible assets", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r88", "r507" ] }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Percentage of voting interests acquired in acquisition", "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination." } } }, "auth_ref": [ "r124" ] }, "us-gaap_BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "BusinessCombinationProFormaInformationEarningsOrLossOfAcquireeSinceAcquisitionDateActual", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual", "negatedLabel": "Net loss before income taxes of acquiree from acquisition date", "documentation": "This element represents the amount of earnings or loss of the acquiree since the acquisition date included in the consolidated income statement for the reporting period." } } }, "auth_ref": [ "r125" ] }, "nhwk_AccruedFranchiseTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "AccruedFranchiseTax", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureAccruedExpensesAndOtherLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAccruedExpensesAndOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable franchise taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Franchise Tax", "terseLabel": "Accrued franchise tax" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual", "terseLabel": "Total revenue of acquiree from acquisition date", "documentation": "This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period." } } }, "auth_ref": [ "r125" ] }, "us-gaap_BusinessAcquisitionProFormaEarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "BusinessAcquisitionProFormaEarningsPerShareBasic", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsSupplementalProFormaFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Pro Forma Earnings Per Share, Basic", "terseLabel": "Net loss per share, basic", "documentation": "The pro forma basic net income per share for a period as if the business combination or combinations had been completed at the beginning of a period." } } }, "auth_ref": [ "r632", "r633" ] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "ScenarioForecastMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Forecast" } } }, "auth_ref": [ "r367", "r607" ] }, "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FiniteLivedIntangibleAssetsNetAbstract", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsCarryingAmountOfGoodwillAndIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net [Abstract]", "terseLabel": "Intangible Assets" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liability, net of current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r461" ] }, "nhwk_IncreaseDecreaseInDepositsOperatingActivity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "IncreaseDecreaseInDepositsOperatingActivity", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 20.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The net cash inflow or outflow for the increase (decrease) in the beginning and end of period deposits balances, operating activity.", "label": "Increase (Decrease) In Deposits Operating Activity", "terseLabel": "Deposits" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "BusinessAcquisitionProFormaInformationTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Pro Forma Financial Information for Acquisition", "terseLabel": "Schedule of proforma operating results", "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate." } } }, "auth_ref": [ "r632", "r633" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liability, current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r461" ] }, "nhwk_WeightedAverageRemainingContractualLifeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "WeightedAverageRemainingContractualLifeAbstract", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Weighted Average Remaining Contractual Life [Abstract]", "terseLabel": "Weighted Average Remaining Contractual Life" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosurePropertyAndEquipment" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r100", "r534", "r535", "r536" ] }, "nhwk_LesseeOperatingLeaseNumberOfSubsequentRenewalTerms": { "xbrltype": "integerItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "LesseeOperatingLeaseNumberOfSubsequentRenewalTerms", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesFacilityLeaseDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of operating lease subsequent renewal terms.", "label": "Lessee Operating Lease Number of Subsequent Renewal Terms", "terseLabel": "Number of lease subsequent renewal terms" } } }, "auth_ref": [] }, "nhwk_AreaOfFacilityToBeLeased": { "xbrltype": "areaItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "AreaOfFacilityToBeLeased", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesFacilityLeaseDetails" ], "lang": { "en-us": { "role": { "documentation": "Area of facility to be leased.", "label": "Area of Facility To be Leased", "terseLabel": "Area of facility to be leased" } } }, "auth_ref": [] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AwardTypeAxis", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWarrantWeightedAverageAssumptionsDetails", "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityAccountingForStockBasedCompensationDetails", "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityChangesInOutstandingWarrantsDetails", "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityRestrictedStockDetails" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395" ] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Maturities of operating lease liabilities" } } }, "auth_ref": [] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "auth_ref": [ "r236", "r367", "r590", "r607" ] }, "nhwk_OperatingLeaseReimbursementOfExpensesToLessor": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "OperatingLeaseReimbursementOfExpensesToLessor", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesFacilityLeaseDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of expenses reimbursed to lessor in an operating lease.", "label": "Operating Lease Reimbursement of Expenses to Lessor", "terseLabel": "Reimbursement of expenses to lessor" } } }, "auth_ref": [] }, "nhwk_MorrisvilleNorthCarolinaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "MorrisvilleNorthCarolinaMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesFacilityLeaseDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information related to Morrisville, North Carolina.", "label": "Morrisville, NC" } } }, "auth_ref": [] }, "nhwk_IncreaseDecreaseInGrantsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "IncreaseDecreaseInGrantsReceivable", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 17.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due under the terms of governmental, corporate, or foundation grants.", "label": "Increase Decrease In Grants Receivable", "negatedLabel": "Grant receivable" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionProFormaEarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "BusinessAcquisitionProFormaEarningsPerShareDiluted", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsSupplementalProFormaFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Pro Forma Earnings Per Share, Diluted", "terseLabel": "Net loss per share, diluted", "documentation": "The pro forma diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period." } } }, "auth_ref": [ "r632", "r633" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.nighthawkbio.com/role/DisclosurePropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property and Equipment", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r85", "r87" ] }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "terseLabel": "Remaining amortization period", "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r507" ] }, "nhwk_MaximumProvisionForTenantImprovementsUnderOperatingLease": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "MaximumProvisionForTenantImprovementsUnderOperatingLease", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesFacilityLeaseDetails" ], "lang": { "en-us": { "role": { "documentation": "The maximum amount of tenant improvements provided for under operating lease.", "label": "Maximum Provision For Tenant Improvements Under Operating Lease", "terseLabel": "Maximum amount of tenant improvements provided for under lease" } } }, "auth_ref": [] }, "nhwk_LesseeOperatingLeaseNumberOfRenewalTerms": { "xbrltype": "integerItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "LesseeOperatingLeaseNumberOfRenewalTerms", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesFacilityLeaseDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of operating lease renewal terms.", "label": "Lessee Operating Lease Number Of Renewal Terms", "terseLabel": "Number of lease renewal terms" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPreliminaryPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "label": "Net liabilities assumed", "totalLabel": "Net assets acquired and liabilities assumed", "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r128", "r129" ] }, "nhwk_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityModifications": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiabilityModifications", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability modifications.", "label": "Right Of Use Asset Obtained In Exchange For Operating Lease Liability Modifications", "terseLabel": "Right-of-use assets obtained upon operating lease modifications" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "BusinessCombinationsPolicy", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Business Combinations Policy [Policy Text Block]", "terseLabel": "Business Combinations", "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy." } } }, "auth_ref": [ "r122" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureLeasesScheduleOfOperatingLeaseLiabilitiesMaturitiesDetailsCalc2": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesFacilityLeaseDetails", "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "terseLabel": "Operating lease liability", "verboseLabel": "Present value of operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r461" ] }, "nhwk_SanAntonioTxMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "SanAntonioTxMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesFacilityLeaseDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information related to San Antonio, TX.", "label": "San Antonio, TX" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://www.nighthawkbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails", "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r597" ] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ComputerEquipmentMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosurePropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Computers", "terseLabel": "Computers", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract", "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Other comprehensive loss:", "terseLabel": "Comprehensive loss:" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Total comprehensive loss", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r137", "r144", "r200", "r202", "r208", "r512", "r520" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "RevenuesAbstract", "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Revenue:" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "terseLabel": "Comprehensive loss attributable to non-controlling interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r138", "r139", "r144", "r200", "r202", "r209", "r513", "r521" ] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ConstructionInProgressMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosurePropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Construction in progress", "terseLabel": "Construction-in-process", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss - NightHawk Biosciences, Inc.", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r46", "r200", "r202", "r210", "r514", "r522" ] }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "BusinessCombinationConsiderationTransferred1", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureAcquisitionsComponentsOfPurchaseConsiderationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsComponentsOfPurchaseConsiderationDetails", "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Business Combination, Consideration Transferred", "totalLabel": "Total purchase consideration", "verboseLabel": "Contingent and deferred cash consideration related to Elusys acquisition", "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer." } } }, "auth_ref": [ "r131", "r132", "r133" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPreliminaryPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "negatedLabel": "Deferred income tax liability", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date." } } }, "auth_ref": [ "r129" ] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "EquipmentMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesFacilityLeaseDetails", "http://www.nighthawkbio.com/role/DisclosurePropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Lab equipment", "terseLabel": "Lab equipment", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncreaseDecreaseInContractWithCustomerAsset", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 18.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Contract with Customer, Asset", "negatedLabel": "Contract receivables", "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time." } } }, "auth_ref": [ "r601" ] }, "us-gaap_DiscontinuedOperationTaxEffectOfDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DiscontinuedOperationTaxEffectOfDiscontinuedOperation", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfDiscontinuedOperationInOperationsStatementDetails", "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Discontinued Operation, Tax Effect of Discontinued Operation", "negatedLabel": "Income tax (expense) benefit from discontinued operations", "negatedTerseLabel": "Income tax expense from discontinued operations", "documentation": "Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r5", "r6", "r7", "r8", "r16", "r20", "r404", "r418", "r422" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "verboseLabel": "Impact of Recently Adopted Accounting Standards", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationsHeldforsaleMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DiscontinuedOperationsHeldforsaleMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfAssetsAndLiabilitiesClassifiedAsHeldForSaleInConsolidatedBalanceSheetsDetails", "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfDiscontinuedOperationInOperationsStatementDetails" ], "lang": { "en-us": { "role": { "label": "Discontinued Operations, Held-for-sale [Member]", "terseLabel": "Held for sale", "documentation": "Component or group of components classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale." } } }, "auth_ref": [ "r2", "r3", "r186" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental Disclosure for Cash Flow Information:" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DiscontinuedOperationPeriodOfContinuingInvolvementAfterDisposal", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Discontinued Operation, Period of Continuing Involvement after Disposal", "terseLabel": "Discontinued operation, period of continuing involvement after disposal", "documentation": "Period of expected continuing involvement with a discontinued operation after the disposal date, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r13" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPreliminaryPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "terseLabel": "Intangible asset - definite-lived (Note 7)", "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date." } } }, "auth_ref": [ "r129" ] }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncreaseDecreaseInOtherCurrentAssets", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 28.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Current Assets", "negatedLabel": "Other assets", "documentation": "Amount of increase (decrease) in current assets classified as other." } } }, "auth_ref": [ "r601" ] }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_EarningsPerShareDiluted", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureNetLossPerShareReconciliationOfNetLossDetails", "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share", "terseLabel": "Net loss per share, diluted - discontinued operations (in dollars per share)", "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPreliminaryPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "label": "Cash acquired", "terseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r129" ] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Noncurrent Assets", "terseLabel": "Increase in other assets", "documentation": "Amount of increase (decrease) in noncurrent assets classified as other." } } }, "auth_ref": [ "r601" ] }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "lang": { "en-us": { "role": { "label": "Discontinued Operations" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfDiscontinuedOperationInOperationsStatementDetails", "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax", "terseLabel": "Net loss from discontinued operations before income taxes", "totalLabel": "Net loss from discontinued operations before income taxes", "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r4", "r5", "r6", "r7", "r8", "r16", "r50", "r176" ] }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of non-cash investing and financing activities:" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureNetLossPerShareReconciliationOfNetLossDetails", "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share", "terseLabel": "Net loss per share, basic - discontinued operations (in dollars per share)", "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfInputsAndValuationMethodologiesUsedDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Contingent Consideration, Liability, Measurement Input", "terseLabel": "Contingent Consideration", "documentation": "Value of input used to measure contingent consideration liability from business combination." } } }, "auth_ref": [ "r448" ] }, "us-gaap_DiscontinuedOperationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DiscontinuedOperationsPolicyTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Discontinued Operations, Policy [Policy Text Block]", "terseLabel": "Discontinued Operations", "documentation": "Disclosure of accounting policy for discontinued operations. Includes, but is not limited to, method of interest allocation to a discontinued operation." } } }, "auth_ref": [ "r9", "r24" ] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 25.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Noncurrent Liabilities", "verboseLabel": "Other long-term liabilities", "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_LandUnderPurchaseOptionsRecorded": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LandUnderPurchaseOptionsRecorded", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Land under Purchase Options, Recorded", "terseLabel": "Land option agreements", "documentation": "The carrying amount as of the balance sheet date of land not owned but under a contract in which the entity has an option to purchase the land." } } }, "auth_ref": [ "r594" ] }, "us-gaap_DerivativeLiabilityMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DerivativeLiabilityMeasurementInput", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWarrantWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Derivative Liability, Measurement Input", "terseLabel": "Fair value measurement input", "documentation": "Value of input used to measure derivative liability." } } }, "auth_ref": [ "r448" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPreliminaryPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "terseLabel": "Other assets", "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r129" ] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesFacilityLeaseDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Leases", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPreliminaryPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "totalLabel": "Total assets acquired", "documentation": "Amount of assets acquired at the acquisition date." } } }, "auth_ref": [ "r129" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPreliminaryPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "negatedLabel": "Accounts payable", "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date." } } }, "auth_ref": [ "r129" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period", "negatedLabel": "Expired", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } }, "auth_ref": [ "r380" ] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWarrantWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding", "terseLabel": "Warrants and rights outstanding, Value", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "APIC", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r398", "r399", "r400", "r604", "r605", "r606", "r634" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Forfeited", "negatedLabel": "Forfeited", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r379" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureLeasesLeaseCostDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesLeaseCostDetails" ], "lang": { "en-us": { "role": { "label": "Lease, Cost", "totalLabel": "Total finance lease cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r472", "r579" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesFacilityLeaseDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r220", "r221", "r322", "r326", "r551", "r553" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Shares", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_GrantsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "GrantsReceivable", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Grant received", "terseLabel": "Remaining grant amount receivable", "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants." } } }, "auth_ref": [ "r593" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPreliminaryPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "negatedTotalLabel": "Total liabilities assumed", "documentation": "Amount of liabilities assumed at the acquisition date." } } }, "auth_ref": [ "r129" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPreliminaryPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "terseLabel": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date." } } }, "auth_ref": [ "r129" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax" } } }, "auth_ref": [] }, "us-gaap_UnrealizedGainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "UnrealizedGainLossOnInvestments", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 27.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Unrealized Gain (Loss) on Investments", "negatedLabel": "Unrealized (gain) loss on investments", "documentation": "Amount of unrealized gain (loss) on investment." } } }, "auth_ref": [ "r67" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of lease cost", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r640" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureLeasesScheduleOfOperatingLeaseLiabilitiesMaturitiesDetailsCalc2": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total minimum lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r473" ] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Costs and Expenses", "totalLabel": "Total operating expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r52" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r67", "r256" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWarrantWeightedAverageAssumptionsDetails", "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityAccountingForStockBasedCompensationDetails", "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityChangesInOutstandingWarrantsDetails", "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityRestrictedStockDetails" ], "lang": { "en-us": { "role": { "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsComponentsOfPurchaseConsiderationDetails", "http://www.nighthawkbio.com/role/DisclosureAcquisitionsNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails", "http://www.nighthawkbio.com/role/DisclosureAcquisitionsTables", "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsChangeInFairValueDetails", "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfInputsAndValuationMethodologiesUsedDetails", "http://www.nighthawkbio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsCarryingAmountOfGoodwillAndIntangibleAssetsDetails", "http://www.nighthawkbio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsDetails", "http://www.nighthawkbio.com/role/DisclosureIncomeTaxDetails", "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r126", "r127", "r429", "r572", "r573" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Net loss before income taxes from continuing operations", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r49", "r157", "r165", "r179", "r258", "r266", "r270", "r272", "r516", "r559" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfInputsAndValuationMethodologiesUsedDetails", "http://www.nighthawkbio.com/role/DisclosureShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r283", "r284", "r288", "r289", "r290", "r291", "r292", "r294", "r295", "r296", "r324", "r337", "r439", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r560", "r611", "r612", "r613", "r654", "r655", "r656", "r657", "r658", "r659", "r660" ] }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsSupplementalProFormaFinancialInformationDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Pro Forma Net Income (Loss)", "terseLabel": "Net loss", "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period." } } }, "auth_ref": [ "r427", "r428" ] }, "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Accrued interest and penalty related to uncertain tax positions", "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r407" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosurePropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Depreciation", "verboseLabel": "Depreciation expense", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r67", "r93" ] }, "us-gaap_GrantsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "GrantsReceivableCurrent", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureRevenueDetails", "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Grants Receivable, Current", "terseLabel": "Grant receivable", "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r593" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureNetLossPerShareReconciliationOfNetLossDetails", "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average common shares outstanding, diluted (in shares)", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r238", "r243" ] }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_EarningsPerShareBasic", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureNetLossPerShareReconciliationOfNetLossDetails", "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations, Per Basic Share", "terseLabel": "Net loss per share, basic - continuing operations (in dollars per share)", "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r48", "r164", "r166", "r175", "r211", "r226", "r228", "r229", "r230", "r231", "r239", "r241", "r242", "r443", "r515" ] }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Unrecognized income tax benefits impact on effective income tax rate", "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate." } } }, "auth_ref": [ "r409" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureNetLossPerShareReconciliationOfNetLossDetails", "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average common shares outstanding, basic (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r237", "r243" ] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsComponentsOfPurchaseConsiderationDetails", "http://www.nighthawkbio.com/role/DisclosureAcquisitionsNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails", "http://www.nighthawkbio.com/role/DisclosureAcquisitionsTables", "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsChangeInFairValueDetails", "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfInputsAndValuationMethodologiesUsedDetails", "http://www.nighthawkbio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsCarryingAmountOfGoodwillAndIntangibleAssetsDetails", "http://www.nighthawkbio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsDetails", "http://www.nighthawkbio.com/role/DisclosureIncomeTaxDetails", "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r429", "r572", "r573" ] }, "us-gaap_BusinessCombinationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "BusinessCombinationsAbstract", "lang": { "en-us": { "role": { "label": "Acquisitions" } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits", "terseLabel": "Unrecognized tax benefit", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r401", "r408" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "verboseLabel": "Basis of Presentation and Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r75", "r214" ] }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "CashCashEquivalentsAndShortTermInvestments", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, and Short-term Investments", "terseLabel": "Cash, cash equivalents and short term investments", "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable." } } }, "auth_ref": [ "r597" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months", "terseLabel": "2024", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r473" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfInputsAndValuationMethodologiesUsedDetails", "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWarrantWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r446" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "EarningsPerShareBasic", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureNetLossPerShareReconciliationOfNetLossDetails", "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "totalLabel": "Net loss per share common share attributable to NightHawk Biosciences, Inc., basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r211", "r228", "r229", "r230", "r231", "r232", "r237", "r239", "r241", "r242", "r243", "r247", "r442", "r443", "r515", "r523", "r557" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesFacilityLeaseDetails" ], "lang": { "en-us": { "role": { "label": "Lease term", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r639" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r473" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r473" ] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "MeasurementInputExpectedTermMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWarrantWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Contractual term", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": [ "r636" ] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "MeasurementInputPriceVolatilityMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWarrantWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Estimated volatility of future stock price", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": [ "r636" ] }, "nhwk_TpbMerchantsIceLlcMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "TpbMerchantsIceLlcMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesFacilityLeaseDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information related to TPB Merchants Ice, LLC.", "label": "TPB Merchants Ice, LLC" } } }, "auth_ref": [] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfAssetsAndLiabilitiesClassifiedAsHeldForSaleInConsolidatedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureLeasesScheduleOfOperatingLeaseLiabilitiesMaturitiesDetailsCalc2": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesMaturitiesOfOperatingAndFinanceLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: imputed interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r473" ] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationNoncurrentAbstract", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfAssetsAndLiabilitiesClassifiedAsHeldForSaleInConsolidatedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Assets, Noncurrent [Abstract]", "terseLabel": "Long term assets:" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "EarningsPerShareDiluted", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureNetLossPerShareReconciliationOfNetLossDetails", "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "totalLabel": "Net loss per share common share attributable to NightHawk Biosciences, Inc., diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r211", "r228", "r229", "r230", "r231", "r232", "r239", "r241", "r242", "r243", "r247", "r442", "r443", "r515", "r523", "r557" ] }, "nhwk_ProcessDevelopmentRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "ProcessDevelopmentRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of process development revenue recognized.", "label": "Process Development Revenue Recognized", "terseLabel": "Process development revenue recognized" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityAccountingForStockBasedCompensationDetails", "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityChangesInOutstandingWarrantsDetails", "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityRestrictedStockDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPreliminaryPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property and equipment", "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date." } } }, "auth_ref": [ "r128", "r129" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPreliminaryPurchasePriceAllocationDetails": { "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "terseLabel": "Inventory", "documentation": "The amount of inventory recognized as of the acquisition date." } } }, "auth_ref": [ "r128", "r129" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureNetLossPerShare" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r244", "r245", "r246", "r248" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit", "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit." } } }, "auth_ref": [ "r29", "r104", "r170", "r529", "r531", "r580" ] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfInputsAndValuationMethodologiesUsedDetails", "http://www.nighthawkbio.com/role/DisclosureShortTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r283", "r284", "r324", "r337", "r439", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r611", "r612", "r613", "r654", "r655", "r656", "r657", "r658", "r659", "r660" ] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "terseLabel": "Schedule of common stock warrants outstanding", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r105", "r108" ] }, "nhwk_AccruedClinicalTrialExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "AccruedClinicalTrialExpenseCurrent", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureAccruedExpensesAndOtherLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAccruedExpensesAndOtherLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to accrued clinical trial expense. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued preclinical and clinical trial expenses" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total Current Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r188", "r196", "r216", "r286", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r433", "r437", "r452", "r580", "r625", "r626", "r643" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureLeasesFacilityLeaseDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r465" ] }, "nhwk_ChangeInFairValueOfContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "ChangeInFairValueOfContingentConsideration", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 5.0 }, "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsNarrativeDetails", "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "documentation": "Change in fair value of contingent consideration.", "label": "Change In Fair Value Of Contingent Consideration", "terseLabel": "Change in fair value of contingent consideration" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfAssetsAndLiabilitiesClassifiedAsHeldForSaleInConsolidatedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent", "terseLabel": "Property and equipment, net", "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r0", "r1", "r18", "r91", "r97" ] }, "nhwk_LicenseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "LicenseCost", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "License costs.", "label": "License Costs", "terseLabel": "License fee received" } } }, "auth_ref": [] }, "nhwk_LiquidityAndCapitalResourcesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "LiquidityAndCapitalResourcesPolicyTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding liquidity and capital resources.", "label": "Liquidity And Capital Resources [Policy Text Block]", "verboseLabel": "Going Concern Uncertainty" } } }, "auth_ref": [] }, "us-gaap_MeasurementInputDiscountRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "MeasurementInputDiscountRateMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfInputsAndValuationMethodologiesUsedDetails" ], "lang": { "en-us": { "role": { "label": "Discount rate", "documentation": "Measurement input using interest rate to determine present value of future cash flows." } } }, "auth_ref": [ "r636" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNetAbstract", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]", "terseLabel": "Purchase price allocation:" } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "RetainedEarningsMember", "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Accumulated Deficit", "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit." } } }, "auth_ref": [ "r184", "r223", "r224", "r225", "r227", "r233", "r235", "r287", "r398", "r399", "r400", "r415", "r416", "r441", "r526", "r528" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current Assets" } } }, "auth_ref": [] }, "nhwk_UnvestedRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "UnvestedRestrictedStockUnitsMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Unvested restricted stock units [Member]", "label": "Restricted stock subject to forfeiture and restricted stock units" } } }, "auth_ref": [] }, "nhwk_PelicanTherapeuticsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "PelicanTherapeuticsIncMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsChangeInFairValueDetails", "http://www.nighthawkbio.com/role/DisclosureGoodwillAndOtherIntangibleAssetsDetails", "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information related to Pelican Therapeutics, Inc.", "label": "Pelican Therapeutics, Inc." } } }, "auth_ref": [] }, "nhwk_PrepaidExpensesAndOtherCurrentAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "PrepaidExpensesAndOtherCurrentAssetsAbstract", "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Prepaid Expenses And Other Current Assets." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfAssetsAndLiabilitiesClassifiedAsHeldForSaleInConsolidatedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r0", "r1", "r18", "r92", "r97" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfAssetsAndLiabilitiesClassifiedAsHeldForSaleInConsolidatedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent", "terseLabel": "Intangible assets, net", "verboseLabel": "Intangible assets, net", "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r0", "r1", "r18", "r91", "r97" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Net Loss Per Share" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwillNoncurrent", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfAssetsAndLiabilitiesClassifiedAsHeldForSaleInConsolidatedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Goodwill, Noncurrent", "terseLabel": "Goodwill", "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r0", "r1", "r18", "r91", "r97" ] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureRevenueTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "terseLabel": "Schedule of opening and closing balances of the Company's accounts receivables", "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth_ref": [ "r39" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale, Unrealized Gain (Loss)", "terseLabel": "Unrealized (loss) gain on available-for-sale securities", "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [] }, "nhwk_ShattuckLabsIncShattuckMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "ShattuckLabsIncShattuckMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Shattuck Labs, Inc. (\"Shattuck\") Member", "label": "Shattuck" } } }, "auth_ref": [] }, "nhwk_CommonStockWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "CommonStockWarrantMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureNetLossPerShareAntidilutiveSecuritiesDetails", "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityChangesInOutstandingWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of common stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Common stock warrants" } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.nighthawkbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r589" ] }, "nhwk_ContingentConsiderationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "ContingentConsiderationPolicyTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "The accounting policy for contingent consideration.", "label": "Contingent Consideration [Policy Text Block]", "terseLabel": "Contingent Consideration" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "DisposalGroupClassificationAxis", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfAssetsAndLiabilitiesClassifiedAsHeldForSaleInConsolidatedBalanceSheetsDetails", "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfDiscontinuedOperationInOperationsStatementDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r186" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPreliminaryPurchasePriceAllocationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsPurchasePriceAllocationDetails" ], "lang": { "en-us": { "role": { "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "totalLabel": "Total purchase consideration", "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r129" ] }, "nhwk_ProcessDevelopmentContractLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "ProcessDevelopmentContractLiability", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of process development contract liability.", "label": "Process Development Contract Liability", "negatedPeriodEndLabel": "Process development contract liabilities, end of period", "negatedPeriodStartLabel": "Process development contract liabilities, beginning of period" } } }, "auth_ref": [] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 1.0 }, "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Fair Value Adjustment of Warrants", "negatedLabel": "Change in fair value of warrant liability", "verboseLabel": "Change in fair value of common stock warrants", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": [ "r67", "r102" ] }, "nhwk_AmountAwardedFromCpritGrant": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "AmountAwardedFromCpritGrant", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount awarded from CPRIT grant.", "label": "Amount awarded from CPRIT grant", "terseLabel": "Amount awarded from CPRIT grant" } } }, "auth_ref": [] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfAssetsAndLiabilitiesClassifiedAsHeldForSaleInConsolidatedBalanceSheetsDetails" ], "lang": { "en-us": { "role": { "label": "Assets held for sale:" } } }, "auth_ref": [] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosureDiscontinuedOperationsScheduleOfAssetsAndLiabilitiesClassifiedAsHeldForSaleInConsolidatedBalanceSheetsDetails", "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Disposal Group, Including Discontinued Operation, Assets, Current", "terseLabel": "Current assets held for sale", "totalLabel": "Total Current Assets", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r0", "r1", "r18", "r92", "r97", "r186", "r187" ] }, "nhwk_MilestonePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "MilestonePayment", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Milestone payment", "label": "Milestone payment" } } }, "auth_ref": [] }, "nhwk_PrepaidManufacturingExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.nighthawkbio.com/20230930", "localname": "PrepaidManufacturingExpense", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Prepaid manufacturing expense.", "label": "Prepaid manufacturing expense", "terseLabel": "Prepaid manufacturing expense" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segments", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r259", "r260", "r261", "r262", "r263", "r264", "r274" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r444", "r445", "r447", "r448", "r451" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Non-Controlling Interest", "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest)." } } }, "auth_ref": [ "r40", "r159", "r171", "r216", "r286", "r313", "r315", "r316", "r317", "r320", "r321", "r452" ] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Number Of Operating Segments", "terseLabel": "Number of operating segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r609" ] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r120" ] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained upon operating lease commencements", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r469", "r579" ] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "OwnershipDomain", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Ownership [Domain]" } } }, "auth_ref": [] }, "us-gaap_OperatingLossCarryforwardsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "OperatingLossCarryforwardsLineItems", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Income Tax", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "OwnershipAxis", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureAcquisitionsNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "auth_ref": [] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueFinancialInstrumentsDetails", "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfInputsAndValuationMethodologiesUsedDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value By Fair Value Hierarchy Level [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r323", "r360", "r361", "r362", "r363", "r364", "r365", "r445", "r478", "r479", "r480", "r564", "r565", "r569", "r570", "r571" ] }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "crdr": "debit", "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "Right-of-use assets obtained upon financing lease commencements", "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability." } } }, "auth_ref": [ "r469", "r579" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Recurring", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r450", "r451" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsChangeInFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Balance at end", "periodStartLabel": "Balance at the beginning", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r153" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueFinancialInstrumentsDetails", "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfInputsAndValuationMethodologiesUsedDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r323", "r360", "r361", "r362", "r363", "r364", "r365", "r478", "r479", "r480", "r564", "r565", "r569", "r570", "r571" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfInputsAndValuationMethodologiesUsedDetails", "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWarrantWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r152" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/DisclosurePropertyAndEquipmentDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/DisclosurePropertyAndEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated depreciation", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r95", "r192" ] }, "us-gaap_OperatingLossCarryforwardsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "OperatingLossCarryforwardsTable", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureIncomeTaxDetails" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Table]", "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization." } } }, "auth_ref": [ "r121" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive (Loss) Income", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r42", "r45", "r141", "r474", "r526", "r527", "r598", "r599", "r600", "r604", "r605", "r606" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r54" ] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "NoncontrollingInterestMember", "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Non-Controlling Interest", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r135", "r340", "r604", "r605", "r606" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfInputsAndValuationMethodologiesUsedDetails", "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfWarrantWeightedAverageAssumptionsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "terseLabel": "Fair Value of Financial Instruments", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Schedule of fair value inputs", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r152" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income", "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge." } } }, "auth_ref": [ "r43", "r44", "r45", "r195", "r518", "r530", "r531" ] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FairValueByLiabilityClassAxis", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsChangeInFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": [ "r154", "r155" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfFairValueFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Level 1", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r323", "r360", "r365", "r445", "r478", "r569", "r570", "r571" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2022", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureBasisOfPresentationAndSignificantAccountingPoliciesNarrativeDetails", "http://www.nighthawkbio.com/role/DisclosureRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r273", "r506", "r567", "r581", "r622", "r623", "r628", "r653" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsChangeInFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": [ "r153" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsScheduleOfInputsAndValuationMethodologiesUsedDetails" ], "lang": { "en-us": { "role": { "label": "Level 3", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r323", "r360", "r361", "r362", "r363", "r364", "r365", "r445", "r480", "r564", "r565", "r569", "r570", "r571" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value of Financial Instruments" } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstrumentsChangeInFairValueDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3." } } }, "auth_ref": [ "r153", "r155" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.nighthawkbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r28", "r580" ] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureFairValueOfFinancialInstruments" ], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value of Financial Instruments", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r450" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2022", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.nighthawkbio.com/role/DisclosureStockholdersEquityRestrictedStockDetails" ], "lang": { "en-us": { "role": { "label": "RSU's", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "45", "Paragraph": "10", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "45", "Paragraph": "11", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "45", "Paragraph": "1D", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721503-107759" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "45", "Paragraph": "3", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "45", "Paragraph": "3A", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "45", "Paragraph": "3B", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "45", "Paragraph": "4", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3A", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "4A", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "4B", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "5A", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "5B", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)(2)", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "5C", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "5D", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "7", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "S99", "Paragraph": "3", "URI": "https://asc.fasb.org/extlink&oid=26872618&loc=d3e7436-122677" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "URI": "https://asc.fasb.org/subtopic&trid=2122178" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.3,4)", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.31)", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "10A", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "11", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "55", "Paragraph": "15", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-03(13))", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868656-224227" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(14))", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "17", "Subparagraph": "(ee)", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "24", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "28", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "8", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "320", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "350", "URI": "https://asc.fasb.org/topic&trid=2144416" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "11", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2510-110228" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "9", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2473-110228" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "3", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "3A", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "25", "Paragraph": "13", "URI": "https://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "50", "Section": "S99", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "30", "Paragraph": "3", "URI": "https://asc.fasb.org/extlink&oid=128088960&loc=d3e3913-113898" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(4)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "30", "Section": "35", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=126965701&loc=d3e15009-113911" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "730", "SubTopic": "10", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)-(d)", "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "25", "Paragraph": "16", "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "30", "Paragraph": "7", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "30", "Paragraph": "8", "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "805", "URI": "https://asc.fasb.org/topic&trid=2303972" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "19", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "20", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "21", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613674-111683" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "7", "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "830", "SubTopic": "230", "Section": "45", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "940", "SubTopic": "20", "Section": "25", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "220", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "220", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "220", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(20))", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "220", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(g))", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03.(a),19)", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "220", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "220", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(12))", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "220", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "220", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "220", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(8))", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r182": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524" }, "r183": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Section": "50", "Paragraph": "6", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "105", "SubTopic": "10", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "105", "SubTopic": "10", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "7", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "45", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "45", "Paragraph": "5", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "50", "Paragraph": "4", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "50", "Paragraph": "5", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "50", "Paragraph": "6", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(23))", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "24", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "235", "SubTopic": "10", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "235", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "235", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "235", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "235", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "235", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "235", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "235", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "235", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(n))", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "45", "Paragraph": "24", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "3", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "4", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "8", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "9", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "10", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "16", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "45", "Paragraph": "7", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "3", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "55", "Paragraph": "15", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "272", "SubTopic": "10", "Section": "45", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "11", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "12", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "29", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "40", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "42", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Section": "45", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Section": "45", "Paragraph": "9", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Section": "50", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "20", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "320", "SubTopic": "10", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "320", "SubTopic": "10", "Section": "50", "Paragraph": "5", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "320", "SubTopic": "10", "Section": "50", "Paragraph": "5A", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "323", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "323", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "326", "SubTopic": "10", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "326", "SubTopic": "20", "Section": "50", "Paragraph": "11", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "326", "SubTopic": "20", "Section": "50", "Paragraph": "13", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "326", "SubTopic": "20", "Section": "50", "Paragraph": "14", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "326", "SubTopic": "20", "Section": "50", "Paragraph": "16", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "326", "SubTopic": "20", "Section": "50", "Paragraph": "5", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "326", "SubTopic": "30", "Section": "45", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "326", "SubTopic": "30", "Section": "50", "Paragraph": "4", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "326", "SubTopic": "30", "Section": "50", "Paragraph": "7", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "326", "SubTopic": "30", "Section": "50", "Paragraph": "9", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "45", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "45", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "440", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "440", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "450", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "450", "SubTopic": "20", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "450", "SubTopic": "20", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "450", "SubTopic": "20", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "13", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "606", "SubTopic": "10", "Section": "45", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "606", "SubTopic": "10", "Section": "45", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "606", "SubTopic": "10", "Section": "45", "Paragraph": "3", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "606", "SubTopic": "10", "Section": "45", "Paragraph": "4", "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130534-203044" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "606", "SubTopic": "10", "Section": "50", "Paragraph": "10", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "606", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "606", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "606", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "606", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "606", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "606", "SubTopic": "10", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "606", "SubTopic": "10", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "606", "SubTopic": "10", "Section": "50", "Paragraph": "15", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "606", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "606", "SubTopic": "10", "Section": "50", "Paragraph": "5", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "606", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "606", "SubTopic": "10", "Section": "50", "Paragraph": "9", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "80", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "80", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "35", "Paragraph": "1D", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "35", "Paragraph": "3", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(ii)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "45", "Paragraph": "10B", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "45", "Paragraph": "25", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "45", "Paragraph": "28", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "10", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "12", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "14", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "15A", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "19", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "20", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "21", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "9", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "20", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "20", "Section": "45", "Paragraph": "2", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "270", "Section": "45", "Paragraph": "3", "URI": "https://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "270", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "19", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "6A", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "830", "SubTopic": "30", "Section": "45", "Paragraph": "17", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "830", "SubTopic": "30", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "830", "SubTopic": "30", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "830", "SubTopic": "30", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "830", "SubTopic": "30", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "830", "SubTopic": "30", "Section": "45", "Paragraph": "20", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "830", "SubTopic": "30", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "842", "SubTopic": "20", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "842", "SubTopic": "20", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "842", "SubTopic": "20", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "842", "SubTopic": "20", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "842", "SubTopic": "20", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "842", "SubTopic": "20", "Section": "50", "Paragraph": "3", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "842", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "842", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "842", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "842", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "842", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "842", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "842", "SubTopic": "20", "Section": "50", "Paragraph": "4", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "842", "SubTopic": "20", "Section": "50", "Paragraph": "6", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "848", "SubTopic": "10", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "30", "Section": "45", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "30", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "50", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "50", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "50", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "50", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "50", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "50", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "50", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "50", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "50", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "50", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "50", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "50", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "50", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "50", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "50", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "910", "SubTopic": "10", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "924", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "926", "SubTopic": "20", "Section": "50", "Paragraph": "5", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "928", "SubTopic": "340", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "220", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "220", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "220", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(25))", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "220", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "220", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "235", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "360", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "220", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "220", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "220", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(21))", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "220", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "220", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "220", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "40", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "40", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "40", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "40", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "40", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "40", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "40", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "948", "SubTopic": "310", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "954", "SubTopic": "440", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "958", "SubTopic": "360", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "958", "SubTopic": "360", "Section": "50", "Paragraph": "6", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "958", "SubTopic": "360", "Section": "50", "Paragraph": "7", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "970", "SubTopic": "360", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "970", "SubTopic": "360", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "970", "SubTopic": "360", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "970", "SubTopic": "360", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "970", "SubTopic": "360", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "970", "SubTopic": "360", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "970", "SubTopic": "360", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "970", "SubTopic": "360", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "970", "SubTopic": "360", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "976", "SubTopic": "310", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "978", "SubTopic": "310", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r548": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r549": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(1)", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r550": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(3)", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r551": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "20", "Section": "55", "Paragraph": "16", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r552": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "20", "Section": "55", "Paragraph": "21", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r553": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "20", "Section": "55", "Paragraph": "22", "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r554": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r555": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "235", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r556": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "235", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r557": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "55", "Paragraph": "52", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r558": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r559": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "31", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r560": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "326", "SubTopic": "30", "Section": "55", "Paragraph": "8", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r561": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "340", "SubTopic": "10", "Section": "05", "Paragraph": "5", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316" }, "r562": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "340", "SubTopic": "10", "Section": "05", "Paragraph": "5", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316" }, "r563": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "55", "Paragraph": "24", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268" }, "r564": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "55", "Paragraph": "69B", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r565": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "55", "Paragraph": "69C", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r566": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r567": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "606", "SubTopic": "10", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r568": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "606", "SubTopic": "10", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r569": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r570": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r571": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "55", "Paragraph": "17", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r572": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "80", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r573": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "80", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r574": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "80", "Section": "55", "Paragraph": "8", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r575": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r576": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r577": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r578": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r579": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "842", "SubTopic": "20", "Section": "55", "Paragraph": "53", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r580": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "852", "SubTopic": "10", "Section": "55", "Paragraph": "10", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r581": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "40", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r582": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "40", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r583": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "40", "Section": "55", "Paragraph": "29F", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r584": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r585": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r586": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r588": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r590": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "450", "SubTopic": "20", "Section": "50", "Paragraph": "10", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r591": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "855", "SubTopic": "10", "Section": "50", "Paragraph": "3", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r592": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r593": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r594": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r595": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r596": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r597": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r598": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "50", "Paragraph": "4", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r599": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "50", "Paragraph": "5", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r600": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "50", "Paragraph": "6", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r601": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r602": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r603": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "235", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r604": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r605": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "45", "Paragraph": "24", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r606": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r607": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "4", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r608": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r609": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "18", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599" }, "r610": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Section": "45", "Paragraph": "13", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r611": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "321", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r612": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "321", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r613": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "321", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r614": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "323", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r615": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "340", "SubTopic": "10", "Section": "45", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r616": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r617": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r618": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r619": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r620": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r621": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "410", "SubTopic": "30", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r622": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "450", "SubTopic": "20", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r623": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "450", "SubTopic": "20", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r624": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r625": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r626": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r627": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r628": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "606", "SubTopic": "10", "Section": "50", "Paragraph": "5", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r629": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "606", "SubTopic": "10", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r630": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "715", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r631": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r632": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r633": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(3)", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r634": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "40", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r635": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r636": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r637": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r638": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "830", "SubTopic": "230", "Section": "45", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r639": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "842", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r640": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "842", "SubTopic": "20", "Section": "50", "Paragraph": "4", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r641": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "842", "SubTopic": "20", "Section": "50", "Paragraph": "6", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980" }, "r642": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "2", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r643": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "852", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r644": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "852", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r645": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r646": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r647": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r648": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r649": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r650": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "860", "SubTopic": "20", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r651": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "912", "SubTopic": "730", "Section": "25", "Paragraph": "1", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r652": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "220", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(b))", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r653": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "FASB", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "40", "Section": "50", "Paragraph": "4H", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r654": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "SEC", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)" }, "r655": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "SEC", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)" }, "r656": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "SEC", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)" }, "r657": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "SEC", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)" }, "r658": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "SEC", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)" }, "r659": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "SEC", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)" }, "r660": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Publisher": "SEC", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)" } } }